speakers 7th annual european life science ceo forum · partnering strategies through...

SUPPORTING ORGANISATIONSORGANISERS

PRESENTING COMPANIES

WELCOM

ESPEAKERS

7th Annual

EUROPEAN LIFE SCIENCE CEO FORUM

for PARTNERING & INVESTING

www.sachsforum.com

04-05 March 2014 Hilton Zurich Airport Hotel

Conference Guide

EU

RO

PE

AN

L

IF

E

SC

IE

NC

E

CE

O

FO

RU

M



WELCOM

ESPEAKERS

Welcome

t back :: next u

Request for PresentationsPlease use the agenda to mark off presentations that you are interested in and email your request to [email protected] after the conference. We will endeavour to send you the requested presentations as soon as we have been granted permission to do so by that specific presenter. Please note that we DO NOT have copies of the slides that are shown during the conference.

Sachs Associates are delighted to welcome you to the:

7th Annual

European Life Science CEOForum for Partnering & Investing4th - 5th March 2014Hilton Zurich Airport Hotel

General Information• The registration desk is open from 8am on both days although you are welcome to join the

event at any time. Please collect a copy of the agenda for information on timing and room allocation for each session.

• Wireless Internet connection is available throughout the venue for the duration of the event. Please ask for an access code at the registration desk.

• The one-to-one meetings are being held in the La Place A and B. Please bring with you a copy of your diary. Should you have any queries about your schedule, the laptop situated by the meeting tables is available for your assistance.

Sachs Associates are delighted to welcome you to the 7th Annual European Life Science CEO Forum for Partnering & Investing. Following its success from previous years, the forum once again provides access to an exciting cross-section of venture-funded and small-cap companies with leading investors and pharmas.

This exclusive and transactional event compliments our Annual Biotech in Europe Investor Forum, held later in the year, but with added focus on Partnering & the pharmaceutical industry, feature presentations from Big Pharma representatives demonstrating their current and future partnering strategies through thought-provoking case studies.

This year’s programme features a series of panels and presentations from leading investment, pharmaceutical and biotech companies, highlighting the current issues surrounding the evolving Finance and M&A market, Partnering activity, Vaccines, Oncology and Biomedical Investment, and includes special keynote speeches, providing an expert outlook on Europe’s Biotech industry. In addition, the event holds exclusive Partnering Workshop Presentations and more than 60 exclusive company presentations from an exciting and diverse range of publicly listed and private life science companies, looking to raise finance and/or find partners.



WELCOM

ESPEAKERS

t back :: next uEvents Diary

2nd AnnualCANCER BIO PARTNERING and INVESTMENT FORUMPromoting Public & Private Sector, Collaboration & Investment in Drug Development19th March 2014 • New York Academy of Sciences • USA

The Sachs Cancer Bio Partnering Forum is designed to bring together thought leaders from cancer research institutes, patient advocacy groups, pharma and biotech to facilitate partnering and funding/investment. We expect around 300 delegates and there is an online meeting system and meeting facilities to make the event transactional. There will also be a track of presentations by research institutes, patient advocacy groups, pharmaceutical companies on partnering and biotech’s seeking licensing/investment.The Forum will feature an online one-to-one meeting system with designated meeting space available to all attendees.

The Forum will cover the following topics in the program:• Advances in Translational Research • Strategies for Small Molecule and Biologicals Drug Development • Deal Making • Public & Private Partnerships • Diagnostics • Immunotherapies and Cancer Vaccines • Case Study

Visit the event website at: www.sachsforum.com/newyork14

14th AnnualBiotech in Europe Forum30th September – 1st October 2014 • Congress Center Basel • Switzerland

The forum is recognised as the leading international stage for those interested in investing and partnering in the biotech and life science industry and is highly transactional. The Forum draws together an exciting cross-section of early-stage/pre-IPO, late-stage and public companies with leading investors, analysts, money managers and pharma licensing executives. Supported and designed by leading figures within Europe’s bio industry, this event will once again be covered by our regular media partners. We expect over 600 delegates and 100 presenting companies.

The 14th Annual is held for the first time in Basel to be close to the largest biopharma hub in Europe and the Congress Center provides meeting space capable of handling several thousand one- to- one meetings as well as significant exhibition space. The Programme will feature twelve plenary panels/workshops covering BD & Licensing in the main therapeutic areas. There will be significant networking opportunities at the Forum and receptions.

View last year’s event at: www.sachsforum.com/zurich13

2nd AnnualMedtech & Diagnostics Innovations Summit13th November 2014 • Düsseldorf • Germany

View last year’s event at: www.sachsforum.com/mdif13

For regular updates, sponsorship, presenting and attending opportunities and further information regarding any of our future events please contact Mina Orda on [email protected]



WELCOM

ESPEAKERS

Speakers

t back :: next u

Alexey Eliseev, Managing Director, Maxwell Biotech Venture Fund

Alexey received his PhD in Chemistry from Moscow State University and MBA from the Sloan School of Management at the Massachusetts Institute of Technology. His career includes over 17 years of experience in academia, biotechnology industry and venture capital.

Dr. Eliseev has been working in the United States and Europe since 1992. Following three years of postdoctoral research in Germany as an Alexander von Humboldt Fellow and in the US, he joined faculty at the department of Medicinal Chemistry, University at Buffalo in 1995 where he was awarded tenure in 2000. In 1999 he co-founded the company Therascope (later Alantos Pharmaceuticals) with a number of prominent founders including French Nobel Laureate Jean-Marie Lehn. The company used a novel drug discovery technology developed in several academic labs, including Eliseev’s group in Buffalo. He joined the company in 2000 and later became Chief Technology Officer of Alantos and President of its US division. Alantos was acquired by Amgen in 2007 for $300 million.

Over the recent years Alexey was involved in starting several biotech companies as a scientist and entrepreneur, including AC Immune (Switzerland) and Boston BioCom (US). Alexey has been working with the Russian-based Maxwell Biotech Venture Fund as its Managing Director since 2009. He is responsible for international activity of the Fund and has managed numerous deals with portfolio companies in the US and Europe.

Alexander Alexandrov, Medical Director & COO, MYR GmbH

Alexander is responsible for the definition and implementation of the medical-clinical strategy for the development projects across the group, with focus on clinical stage products. Integration of the input from development partners and KOLs into development plans. Support of development teams in medical and scientific issues.

Also, the upervision of in–house and subcontracted research activities with focus on chronic viral hepatitis, business development.

His recent accompliments include: Closeing the deal with VC funds HTGF and Maxwell Biotech; initiating and completing a first-in-man Phase 1 clinical trial with the company’s lead product Myrcludex B for treatment of chronic hepatitis B and D infections; and initiating a Phase 2 trial in indication chronic hepatitis infection (ongoing).

Andrey Vvedensky, Director, Infrastructure Development Department, RVC

Andrey graduated from The Russian Foreign Trade Academy of the Ministry for Economic Development of Russia with honors degree.

From 2001 till 2007 Mr. Vvedensky had private consultancy practice, was member of the management board of a private investment fund, where is terms of reference included investments into high-tech companies, projects ordered by governmental and commercial institutions of the technology sector, and cooperation with one of the leading Russian banks on infrastructure investment projects.

Since 2008 Andrey Vvedensky is in charge of strategic development, business planning and promotion of venture investment tools on the Russian market in the RVC. Mr. Vvedensky was member of the team that launched RVC’s Tender Two. Additionally, he was part of the decision-making process and investment project expertise, cooperating with management companies, portfolio companies and independent experts.

His track record also includes supervision of the launch of the RVC Seed Fund. As RVC’s Director of Department of Infrastructure Development, Mr.Vvedensky is in charge of RVC’s operations with elements of technological market’s infrastructure, start-up and management of RVC’s new investment products, control RVC’s infrastructure initiatives and projects’ execution, strategic programs, including seed companies infrastructure and globalization program. Additionally, he is member of the Board Director of RVC Seed Fund.

As a part of institutional development, different projects for modernization of legislation related to intellectual property, pooled investments and corporate governance in sphere of innovative and technological enterprise are realizing under Andrey Vvedensky management.



WELCOM

ESPEAKERS

t back :: next u

Speakers

Arthur Franken, Partner, Gilde Healthcare

Arthur joined Gilde in 2001. He led the investments in Conatus Pharmaceuticals (IPO on NASDAQ), FlowCardia (acquired by C. R. Bard), Moximed and MTM Laboratories (acquired by Roche). He has been involved in numerous investments and divestments including Ablynx (IPO on Euronext), Agendia, uniQure, BG Medicine (IPO on NASDAQ) and Pieris.

He represents Gilde on the board of Moximed and Symphogen. He served as a board member for FlowCardia until its trade sale to C. R. Bard, MTM Laboratories until its trade sale to Roche and observed on the boards of Agendia and AMT until its IPO on Euronext.

Prior to joining Gilde he gained experience in cardiovascular research at the Leiden/Amsterdam Center for Drug Research and TNO. He holds a masters degree in Biopharmaceutical Sciences from Leiden University, the Netherlands. He is a Dutch national.

Bernhard Courtieu, CEO, IntegraGen

Dr Courtieu joined IntegraGen as CEO in 2007. Prior to joining the company, he achieved significant success in the role of Practice Leader and later as Vice President within Gemini Consulting’s Life Sciences Divison in France. During his tenure with Gemini Consulting and Cap Gemini Ernst and Young he yielded hands on experience in improving the operational performance of pharmaceutical companies in the fields of research and development, industrial operations, supply, sales and marketing and information systems. Previous to this, Dr. Courtieu held the position of Country Manager, France at Ariba, the world leader in spend management. In this role, he assisted companies in analyzing and managing their corporate spending in order to acheve increased buisiness proficiency. Dr. Courtieu holds an MBA from the Instituto De Las Estudios Superiores De La Empresa, in Barcelona, Spain. He recieved his doctorate in Veterinary Medicine from the Ecole Veterinaire d’Alfort and University Paris Xll, France.

Bernhard Sixt, Chief Executive Officer, ImmunID

Dr Sixt has over 25 years of pharmaceutical industry experience in the development and commercialization of laboratory services, in vivo and in vitro diagnostics, and pharmaceuticals for industry leaders such as Amersham (now part of GE Healthcare), and Nycomed (now part of Takeda). He is a co-founder of Agendia and has served as the company’s CEO from 2003 until 2011. Dr. Sixt holds a Master of Science degree in Biochemistry and Chemistry from Ludwig Maximilians University, and a PhD from the Technical University, both in Munich, Germany.

Carles Domènech, CEO, Ability Pharmaceuticals

Carles obtained a BSs/MSc degree in biology (first class honors) from the Autonomous University of Barcelona and also a PhD degree in cellular biology from the same University, working at the Council of Science Research (CSIC). He has additional business training at ESADE business school and other business programs.

Carles started developing his career in cancer research at CSIC in Barcelona (1985-89) and at Memorial Sloan-Kettering Cancer Center in New York (1990-1992).

Carles has 15 years international experience in business development and licensing in the pharmaceutical industry. He held senior positions at the Barcelona pharmaceutical companies Almirall, SA (1992-2003, Manager and Head, Business Development and Licensing) and Lacer, SA (2005-2007, Director, Business Development and Licensing).

Carles has also 4 years’ experience in biotech venture capital and business angels associations and has also been collaborating with government innovation agencies. Between 2004 and 2005 he was Director, Biotech Investments at the seed venture capital firm Barcelona Emprèn, SCRSA. During 2008-2009 he collaborated with agencies of the Government of Catalonia as Director, Technology Transfer and Valorization and as Managing Director, Investment and Enterprise Growth. He had under his responsibility the seed venture capital company Invertec, SA and the entrepreneurship finance programs Genesis Capital and Concept Capital. Since July 2009 he also advises Keiretsu Forum Barcelona in biotech investments.

In 2009 Carles cofounded Ability Pharmaceuticals, SL to become its Chief Executive Officer in September 2009.



WELCOM

ESPEAKERS

t back :: next u

Speakers

Chris Maggos, Business Development, Alpine Institute for Drug Discovery SA

Chris has 20 years of experience in the life sciences industry covering business development, investor relations, communication, investing and molecular neurobiology. Most recently, Chris has been working to establish the Alpine Institute for Drug Discovery, a social enterprise focused on translational drug discovery of novel immunotherapeutics via open innovation. Prior to launching AIDD, Chris was a member of the executive management board at Addex Pharmaceuticals and held the positions of head of investor relations & communication (2007-2010) and director of business development (2010-2013). Previously he worked as: a journalist for the biotechnology trade publication BioCentury (2001-2007); an investor at a NYC-based biotechnology hedge-fund (1997-2000), called Casdin Life Science Partners (later called Cooper Hill); and a molecular neurobiologist studying drug dependence at The Rockefeller University (1993-1997). He is co-author on 12 peer-reviewed publications. Chris holds a BA from Yale University in English Literature (where he also completed pre-medical studies).

Christian Homsy, CEO, Cardio3 BioSciences

Christian has been the Chief Executive Officer (CEO) of Cardio3 BioSciences since its inception. Christian gained his business experience in senior research and development, marketing, business development and sales positions, at Guidant Corporation, a leading medical device company active in the treatment of cardiovascular disease. He was also founder of the Guidant Institute for Therapy Development, a landmark facility for physician and health care professionals’ education that gained international recognition and praise. Christian excelled in building businesses with well-respected teams, setting standards inside and outside the organization. Before joining Cardio3 BioSciences, Christian was General Manager of Medpole, a European incubator dedicated to initiating the European operations for start-up companies in the medical device or biotechnology fields. Christian is a physician by training and received a MBA from the IMD in Lausanne, Switzerland. Christian holds a director mandate in Medpole SA.

Chris Britten, Head, Business Development, Sanofi Pasteur MSD

Chris is Head of Business Development at Sanofi Pasteur MSD, the leading European vaccine company. Sanofi Pasteur MSD is a joint venture between Sanofi Pasteur, the vaccine division of Sanofi, and Merck & Co (known as MSD outside the US and Canada). The company is dedicated exclusively to vaccines and develops Sanofi Pasteur’s and Merck’s vaccines from phase IIb onwards for commercialization in 19 Western European countries.

Chris joined the company in 2013 to lead the company’s efforts to acquire new products to drive future revenue growth. With a strong late-stage development and commercialization infrastructure coupled with leadership within the vaccine industry, Sanofi Pasteur MSD is ideally placed as the partner of choice to bring new products to the European market.

Prior to joining Sanofi Pasteur MSD, Chris was Business and Commercial Development Director at Astellas Pharmaceuticals (Europe) with global franchise responsibility for anti-infectives and kidney disease. He joined Astellas from Deloitte Corporate Finance where he lead the Life Science Advisory team in London advising clients on all aspects of corporate transactions (M&A, divestments, partnerships/licensing, fund-raising, valuation, stock-market listing/delisting etc). Clients included corporates and private equity investors across the spectrum of biotechnology, pharmaceuticals, medical devices and diagnostics.

Chris joined Deloitte from GlaxoSmithKline plc where he spent 6 years as Business Development Director covering licensing, acquisitions, divestments and equity investments across all asset classes (compounds, technologies and IP). He joined GSK in 1992 as a research scientist and spent 10 years in drug discovery before moving into corporate development roles.

He holds a PhD in Biochemistry from the University of Pennsylvania and an MBA (with distinction) from London Business School. Chris is also Managing Director of Vantage Life Sciences, a corporate strategy and transactions advisory firm.



WELCOM

ESPEAKERS

t back :: next u

Speakers

Dan J Gelvan, Managing Director, Life Sciences, Arum Ventures MKI Ltd

Dr Dan Gelvan is a seasoned life-science executive who before joining Aurum Ventures managed GammaCan International, Inc., a development-stage pharmaceutical company. Previously, Dr. Gelvan founded and managed Zetiq Technologies, a drug discovery company specializing in cell-based high-throughput screening for novel anti-cancer drugs. Dr. Gelvan founded Zetiq after leaving a senior position in Clal (Israel) Ltd., one of Israel’s largest holding conglomerates. Dr. Gelvan holds a PhD in Business Economics from RUC in Denmark, and a BA and MA in Economics from the Hebrew University in Jerusalem. Dan is an experienced lecturer of corporate finance and entrepreneurship. Dr. Gelvan was a member of Israel’s National Committee for Biotechnology for an extended period of time. Dr. Gelvan is currently on the boards of: LifeBond, VBL Pharmaceuticals, CorAssist, Nephera, Beta-O2, Noblegen, Vecta and I2O Pharma.

David Colpman, Head of Global Business Development, Shire

David leads Shire’s Global Business Development Department. His role encompasses Licensing and M&A.

David joined Shire 14 years ago, and under his leadership the BD team has helped to build Shire as a leading Bio Pharmaceutical Company. In 2013 the team completed 4 M&A’s including the $4.2bn acquisition of ViroPharma.

David acts as advisor to the Venture Group, Sunstone Capital and was formerly a member of the board of Ace BioSciences.

Prior to joining Shire he led GlaxoWellcome’s UK Business Development team and prior to that he was Head of Licensing and Alliances at Novo Nordisk in Denmark. David is a member of the Royal Pharmaceutical Society: he spent part of his early career working in Japan and has a basic command of the Japanese language.

Dieter Ziegler, Director, Ventures & Early Stage Collaborations, AbbVie

Dieter is Director of Venture Investments & Early Stage Collaborations. Dieter is primarily responsible for identifying and transacting both Venture and early stage opportunities across therapy areas including immunology, oncology, virology, renal disease and neuroscience.

Dieter has almost thirty years of experience in the pharmaceutical industry from early stage discovery through clinical development phase 2, with a focus on cardiovascular and renal indications. He worked for almost 25 years in different functions with a Belgian-based Pharmaceutical company until it was acquired by Abbott Laboratories late 2009. These different functions include Group Leader in Cardiovascular Pharmacology, Project Manager Cardiology, Department Head of Pharmacology, Research Program Manager Cardiology. His final position before the Abbott acquisition was Head of Scouting, Alliances and Portfolio where he built an international team located across Europe. In 2011 he started his position in External Research in Ludwigshafen, Germany.

Dieter obtained his DVM from the Veterinary School in Hannover, Germany. He holds a Ph.D. in Laboratory Animal Sciences from the Medical School Hannover, Germany.

Christina Takke, Partner, Forbian Capital Partners

Christina holds a PhD in Developmental Biology, which she obtained under the supervision of Prof. Dr. Campos-Ortega at the Institute of Development Biology of the University of Cologne. As an undergraduate Christina studied Molecular Biology / Biochemistry at the Technical University of Darmstadt, Université de Bordeaux and at the Institut National de la Recherche Agronomique (INRA) Montpellier. After her studies, she gained experience in working with biotech startup companies at Bio-Gen-Tec-NRW in Cologne, Germany, a regional development organization for the biotechnology industry. She evaluated business proposals and assisted the young biotech companies in the fundraising process. Christina joined the ABN AMRO Capital Life Sciences team as an analyst in 2000. Following this assignment she became Principal before being promoted to Partner. At Forbion Christina is responsible for scouting and analysis of new investment opportunities as well as general deal execution. Christina currently serves on the supervisory boards of Forbion’s portfolio companies Amakem NV, arGEN-X BV, and Pieris AG. In recent years she served on the board of Bioceros, and she was closely involved with GlycArt AG as a Board Observer (sold to Roche in 2005).



WELCOM

ESPEAKERS

t back :: next u

Speakers

Duncan Young, Business Development Manager, MRC Technology

Duncan has a wealth of experience in technology transfer and translational research form his time at MRC Technology. With a background in neurodegeneration, specifically prion diseases and protein structure, Duncan worked for the UK government at Defra in research oversight of their Transmissible Spongiform Encephalopathy portfolio. From there, Duncan joined MRCT as a Business Manager involved in the identification, protection and commercialisation of MRC intellectual property. As MRCT business model changed, Duncan moved into a newly created role of Business Development Manager to promote MRCT’s collaborative drug discovery capabilities, find new collaborative projects within academia and industry, and then source a commercial partner to help develop those projects to the clinic. In recent years, Duncan has been responsible for commercial licences of over £25m in value, and led with Alzheimer’s Research UK on the formation of the Dementia Consortium, a novel business model to bring together the charity and Pharma sectors to drive new therapies to the clinic.

Eduardo Bravo, CEO, TiGenix NV

Eduardo has more than 20 years experience in the pharmaceutical industry. He held several senior management positions at Sanofi-Aventis, including Vice President for Latin America, a division with 2000 employees and sales of more than EUR 1 billion. At Sanofi-Aventis he also held senior positions in Marketing and Sales for Europe and he was General Manager for Belgium. Prior to his tenure at Sanofi-Aventis, Mr. Bravo spent 7 years at SmithKline Beecham in sales positions both nationally and internationally. Mr. Bravo holds a degree in Business Administration and an MBA (INSEAD), and is co-Chair of the Alliance of Advanced Therapies.

Elena Startseva, Head of Business Development, OCT-Clinical Trials

As a Head of Business Development, Elena is responsible for new business opportunities assessment and management; she supervises OCT’s marketing activities and strategic partnerships.

Elena has started working in the Pharmaceutical/CRO industry in 2005 as a CRA with Quintiles and has a deep knowledge and expertise in the field of clinical research.

After several years of experience in project management positions at Quintiles and then OCT, Elena was appointed to lead the Business Development team.

Elena holds Doctor of Medicine degree from the St. Petersburg Peadiatric Medical Academy, she completed residencies in forensic and general pathology, and an MBA degree in International Business from Stockholm’s University.

Emanuel Noam, CTO, PolyPid Ltd

Dr. Emanuel has vast experience in biotechnology projects, including development of drug delivery systems and immunology. His extensive expertise includes immunotherapy, vaccines, immunodiagnostics, systemic and local drug-delivery, and medical devices. Dr. Emanuel has a number of approved patents in the field of drug delivery and diagnostics. Dr. Emanuel is a co-founder of PolyPid and served as its CEO during the company’s first three years. He received his Ph.D. degree from the Faculty of Medicine at the Hebrew University of Jerusalem.

Esteban Pombo Villar, COO, Oxford BioTherapeutics

Esteban is Chief Operations Officer for Oxford Biotherapeutics. Prior to joining OBT, Dr Pombo-Villar was at Novartis for over 20 years, the last 12 years of which he focused on all aspects of creating and managing alliances. Most recently he was Head of Alliance Management at the Novartis Institute for Biomedical Research (NIBR), responsible for alliances up to proof-of-concept in man. He has a PhD in organic chemistry and completed postdoctoral studies at the ETH in Zurich before joining Sandoz Neuroscience Research in Basel in 1988. At Sandoz he worked on drug discovery projects as well as leading collaborative projects investigating the potential of emerging technologies. Dr Pombo-Villar is a Fellow of the Royal Society of Chemistry.



WELCOM

ESPEAKERS

t back :: next u

Speakers

Florian Fischer, CFO, Affimed Therapeutics AG

Florian joined Affimed in 2005 as CFO. He has a strong track record as lead advisor in a variety of transactions and financings in the life sciences and health care sector. Dr. Fischer is founder and CEO of MedVenture Partners — a Munich based corporate finance and strategy advisory company focusing on the life sciences and health care industry. Prior to founding MedVenture Partners, Dr. Fischer worked with KPMG for more than six years, where he was responsible for biotech and healthcare assignments. Before joining KPMG, he worked for Deutsche Bank AG. Dr. Fischer holds a graduate degree in business administration and a PhD in public health.

Gilad Peleg Lorberbaum, Chief Operating Officer, Rainbow Medical

Gilad Peleg Lorberbaum has more than 20 years of senior management experience in the Life Sciences Industry. Currently as C.O.O at Rainbow Medical, an operational invest company that had incorporated and invested in 12 portfolio companies, 25 pipeline projects, with total investments reaching $100M. Gilad is the former CEO of NanoCyte Inc., a drug delivery company that had developed an incomparable topical delivery platform technology, leveraging micron size sea life injectors for effective trans-dermal delivery of pharmaceuticals and cosmetics. Prior to, Gilad was VP at Reico Venture Capital, managing a portfolio of 12 med-tech companies, and earlier on a Director of Business Development at Teva Pharmaceutical Industries (NASDAQ: TEVA), and Director of Finance at Teva Pharmaceuticals R&D division. Gilad was also involved in Private Equity transactions, as well as a Co- Founder of a cancer detection technology turn around. Gilad holds a BA in Economics from the Hebrew University of Jerusalem, Israel, and an MBA from the Hartford University, Connecticut, USA.

Fintan Walton, CEO, PharmaVentures Ltd

Dr Fintan Walton is the Founder and CEO of PharmaVentures. He was educated at the University of Michigan (US) and Trinity College (Dublin, Ireland), and subsequently he gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992). As an entrepreneur, Dr Walton co-founded CONNECT Pharma in 1992, a company focused on assisting pharmaceutical and biotechnology companies worldwide in all aspects of deal making including strategic alliances, Mergers & Acquisitions and equity financing. In 1997 the company became PharmaVentures. His company has worked with blue chip clients on a global basis, delivering more than 600 assignments for companies in 37 countries. Clients have included major pharmaceutical and biotechnology companies as well as diversified chemical corporations, medical device, generic and OTC companies. His clients have also included major banks, investment/merchant banks, and private equity and venture capital groups. Although Fintan’s main focus is his role as Chief Executive Officer of PharmaVentures, he actively participates in many consultancy assignments.

Guillaume Vignon, Director Business Development Oncology - Global Business Development and Licensing, EMD Serono

Guillaume Vignon is Director of Business Development Oncology at Merck/EMD Serono, responsible for leading business development initiatives, designing deal structures, and negotiating terms of strategic partnerships in the field of Oncology. Guillaume hold several positions within Global Business Development and Licensing with increasing responsibilities in all aspects of deal making. During his career at Merck/EMD Serono, Guillaume closed successfully several complex transactions and forged key partnerships in the fields of Oncology, Companion Diagnostic, and Antibody Discovery, strengthening Merck/EMD Serono’s portfolio of innovative products and enhancing R&D capabilities in the field of Biologics.

Recently, Guillaume was the business development lead of the collaboration between Merck and BeiGene, which has received the 2013 BayHelix Elsevier Alliance of the Year Award recognizing a ground breaking pharmaceutical collaboration agreement involving a Chinese entity.

Guillaume holds an MBA from Hult International Business School, Cambridge, USA, and a Ph.D. in Biochemistry and Molecular Biology from the University of Paris 6/ Pasteur Institute, Paris, France.



WELCOM

ESPEAKERS

t back :: next u

Speakers

Jan Groen, Chief Executive Officer, MDxHealth

Dr Jan Groen joined MDxHealth in 2010 and has more than 25 years of experience in the clinical diagnostic industry, with a particular focus on emerging technologies, product development and commercialization. Dr. Groen was previously the president and COO of Agendia and, responsible for their United States and European diagnostic operations. Prior to this, he served as vice-president of research & development at Focus Diagnostics, Inc., a subsidiary of Quest Diagnostics, in California. Dr. Groen has held numerous management and scientific positions at ViroClinics B.V., the Erasmus Medical Center, and Akzo-Nobel. Dr. Jan Groen is a supervisory board member of IBL International B.V. Dr. Groen holds a Ph.D. degree from the Erasmus University Rotterdam and published more than 125 papers in international scientific journals in the field of clinical diagnostics.

Hendrik Liebers, CFO, Probiodrug AG

Prior to joining Probiodrug as Chief Financial Officer, Hendrik Liebers spent appr. 8 years in the investment business, where he successfully executed several private placements, trade and asset sales, fund in fund investments, M&A as well as licensing and codevelopment transactions in Europe and the USA. From 2004 to 2007 he had the position of Head Life Science at IBG Sachsen-Anhalt being responsible for IBG’s Life Science team and activities. From 1998 to 2004 he worked as investment director with Sachsen LB Corporate Finance Holding GmbH (CFH). He served as Vice Chairman of Probiodrug’s Board of Directors until 2007. Hendrik Liebers graduated from the Universities of Leipzig and Tuebingen as a Bachelor of Biology with a focus in biochemistry, developmental biology and plant genetics and obtained a Bachelor of Commerce at the Universities of Leipzig and Hagen.

Hans Herklots, Managing Director, Capricorn One

Hans has close to 25 years of strategic communications experience in the life sciences industry, from small biotech and medtech to bellwether biotech and top tier pharma. He has managed the communication aspects of many corporate transactions, strategy shifts, crises, restructurings, and management changes for public and private companies in Europe, the US and Canada. Leveraging his broad and deep international network in the media and investor communities, he has assisted life science companies to raise their profiles, build their reputations, and attract funding. He has been involved in raising more than EUR 700 million in private financings, M&A transactions and IPOs. Hans has published on a wide range of topics, including drug development and the history of science.

Jason Coloma, Global Head Venture & Innovation at Roche Partnering, F.Hoffmann La Roche AG

Jason is the Head of Venture and Innovation in Roche Partnering responsible for (1) external innovation with academia and venture capitalists (2) new modalities or technology platforms that can potentially be applied across therapeutic areas (3) opportunities in adjacent sectors that may translate into innovative solutions for patient care, including healthcare IT.

Jason was previously Head of the Diagnostics Program Office responsible for supporting the Diagnostics Chief Operating Officer in various strategic initiatives and partnering activities. Jason led a number of partnering activities including commercial and academic agreements, mergers and acquisitions as well as strategic investments. He also oversaw Divisional Portfolio Management as well as Market and Competitive Intelligence.

Prior to his time at Roche, Jason worked in the biopharmaceutical industry both as a strategy consultant and working in operational roles. As a strategy consultant, he primarily worked with biotechnology start-up companies venture capital and private equity firms working on a range of issues including partnering deal support, evaluating the business opportunity of innovative discoveries and implementing external innovation models. Jason also held research and business positions at Amgen, the University of California, San Francisco as well as biotechnology startups.

Jason completed his graduate studies in Immunology at the University of California, Berkeley as well as his MBA from the Tuck School of Business at Dartmouth.



WELCOM

ESPEAKERS

t back :: next u

Speakers

Jasper Bos, Director, MS Ventures

Jasper is Director with MS Ventures, the corporate venture arm of the prescription medicines division of Merck KGaA, Darmstadt, Germany. Prior to joining MS Ventures, Jasper was instrumental in the founding of IFHA, a private equity fund investing in the healthcare and insurance sectors in emerging economies. Before IFHA, Jasper worked as health economics and strategy manager at the Netherlands Vaccine Institute.

Currently, he is a Member of the Board of Directors of Asceneuron, EpiTherapeutics, Galecto Biotech, Neviah Genomics, Prexton therapeutics, Calypso Biotech, ObsEva, and an Observer to the Board of Vaximm. He holds a PhD in Pharmacy from the University of Groningen, the Netherlands.

Jeroen Tonnaer, Executive Director Business Development Head European External Scientific Affairs, MSD

Jeroen Tonnaer PhD obtained an MSc in biology from the University of Nijmegen and a PhD in pharmacology from the Medical Faculty (Rudolf Magnus Institute for Pharmacology) of the University of Utrecht. Part of his PhD work was performed at the INSERM laboratories in Paris.

Jeroen joined Organon as a neuroscientist in 1982. As Assistant-Manager of the CNS Program he was responsible for the pre/early clinical development of SAPHRIS®/SYCREST® (asenapine). He held further positions as Head DMPK, Executive Director Toxicology, Executive Director Global Research Alliances and, upon acquisition of Organon by Schering-Plough, Head Discovery Collaborations Europe. In the latter role he led the team that facilitated licensing and collaborative efforts for the Schering-Plough scientists based in Europe, focused personally on the Women’s Health field and was the business liaison for Schering-Plough in the consortium TI Pharma.

Following Schering-Plough’s acquisition by Merck, Jeroen joined Merck’s Worldwide Licensing organization in February 2010 to become head of the European External Scientific Affairs team. Since then this team has been the driver in the identification and execution of several major licensing and partnering deals including those with Ablynx, AiCuris and Delphi Genetics.

Jason Rushton, Director, Corporate Finance, Deloitte

Jason is a Director in Corporate Finance and is responsible for advising and managing the Swiss life science client base.

He has over 20 years of experience in the pharmaceutical sector including R&D, management consulting and venture capital.

Jason has been a board member of a number of life science companies and has first hand experience of business development and licensing.

Jesse Schulman, CEO, Canbex Therapeutics Ltd

Jesse has been the CEO of UCL spin-out Canbex Therapeutics since 2012, and has worked with the firm as a consultant since 2009. In April 2013, he helped Canbex close a $3.2m fundraising round that was led by new investor Merck Serono Ventures, along with existing investors UCL Business and the Wellcome Trust. The Series A will allow Canbex to complete its current Phase I trial of the firm’s lead compound, VSN16R, which is aimed at the treatment of spasticity in people with multiple sclerosis, and prepare for Phase II. Jesse Schulman was trained as a Neuroscientist at UC San Diego and the Salk Institute, and has worked extensively in corporate finance for the biotech sector, helping firms execute fundraising, licensing and M&A transactions.



WELCOM

ESPEAKERS

t back :: next u

Speakers

Julia Sardaryan, Director of Corporate Development, Smooth Drug Development

Julia joined Smooth Drug Development at 2013. Julia is a managing partner and Director of Corporate Development at Smooth Drug Development. Julia is responsible for driving the company’s growth as a leading provider of clinical trials and consulting services to pharmaceutical and biotechnology companies.

Smooth Drug Development is a drug development company engaged in drug development from animal studies to drug registration and commercialization in Russia and CIS.

Julia started her career in CRO business at OCT in 2007. Through the years she has demonstrated career development being Clinical Trials Coordinator, Business Development Manager and then Director of Business Development at OCT.

Julia graduated from St-Petersburg State University in 2007. Julia holds a masters degree in English Linguistics, Translation.

John Haurum, CEO, F-star

John joined F-star as the CEO in May 2012. Previously he was VP Research at ImClone Systems, New York (2010-2012). Before then he was the Chief Scientific Officer and a cofounder of Symphogen A/S, Denmark (2000-2009).

After graduating in Medicine in Aarhus Denmark 1992, Dr. Haurum received a D.Phil. in Immunology from the Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, England. Subsequently, he took up a position as Associate Professor at the Danish Cancer Society and completed his medical training.

Jørgen Thorball, Managing Partner, XOventure GmbH

Dr. Jørgen Thorball, Managing Partner, XOventure GmbH and CEO of Ophiuchus Technologies AG started his first two companies in the early 1980s.

During the years Jørgen Thorball has been raising +€300 Million from private, corporate and venture capital and have established more than 30 companies, and is currently co-founder & chairman of several the companies. In 2006 he co-authored two books on innovation and is today frequent speaker at seminars as well as executive MBA courses.

Katya Smirnyagina, Partner, Capricorn Venture Partners

Dr Ekaterina Smirnyagina is a Partner at Capricorn Venture Partners (Belgium) since 2012. Prior to this, she worked for ten years at Alta Partners, a healthcare focused venture capital fund in San Francisco, CA. She has a PhD in Cellular & Molecular Biology (University of Wisconsin-Madison, USA), BS in Biochemistry (Lomonosov Moscow State University, Russia). Katya completed her scientific training at the Stanford University School of Medicine, then worked in management consulting and biotech business development. She represents Capricorn on the board of iSTAR Medical SA and Nexstim Oy, and serves as independent board member of Adocia SA (NYSE Euronext: ADOC.PA).

Kevin Cox, CEO, Imanova Ltd

Kevin Cox is CEO of Imanova Limited, a unique joint venture between the MRC and London’s three leading university colleges, Kings, Imperial and UCL. Established in 2011 with the acquisition of GSK’s renowned Clinical Imaging Centre, Imanova and its partners have world-leading expertise to drive research and innovation in imaging sciences, directly benefiting our understanding of disease and improving drug development.

Kevin’s experience includes establishing and leading innovative, high-growth businesses, working with the NHS and academia, and the design and implementation of innovative Public/Private partnerships. Additionally, Kevin is experienced in biopharmaceutical development – both clinical and non-clinical, laboratory diagnostics development and service provision, and the translation of new technology for clinical and commercial benefit.

Kevin has held a number of public sector roles, namely Chair of UKTI’s Bio/Pharma Sector Advisory Committee, Chair of BioNow Advisory Committee, a member of the UK Life Sciences Marketing Strategy Board. He currently sits on the TSB’s advisory board for stratified medicine and is a non-executive director of the British Neuroscience Association (BNA) and the BIA.



WELCOM

ESPEAKERS

t back :: next u

Speakers

Laurent Choppe, Managing Partner, Cukierman and Co. Life Sciences

Laurent Choppe is leading Cukierman & Co. Life Sciences since 2008 and was involved in all Israeli and international medical device and biotech transactions for the Cukierman group. He brings an extensive international life science experience in managing multifunctional teams and setting up new businesses in pharmaceuticals, biotechnology, nutraceuticals, animal health and direct-to-consumer markets. After a veterinary practice and a new venture management experience, he joined Schering-Plough in 1994 by leading the marketing of major drugs in dermatology, allergy, respiratory and animal health in France, became General Manager in Israel and moved up to Vice President, Virology, Oncology and Cardiology in Canada. He then served as the General Manager of the international headquarters of BELLUS Health (ex-Neurochem NASDAQ & TSE), a global pharmaceutical and nutraceutical company addressing unmet needs in Alzheimer’s disease, AA amyloidosis, diabetes, memory and cognition.

Dr. Choppe is a Doctor of Veterinary Medicine of the University Paris XII, laureate of the École Nationale Vétérinaire d’Alfort, CES of Veterinary Ophthalmology and earned a MBA from INSEAD in Fontainebleau (France). He is married, father of 3 and lives in Lausanne (Switzerland).

Kirill Kaem, Executive Director of BioMedical Technologies Cluster, Skolkovo Foundation

Kirill’s family have been doctors for no fewer than seven generations, graduated from the Kirov State Medical Academy in Nizhny Novgorod in 1992. Five years later he graduated with distinction from the economics department at the Lobachevsky State University, after successfully completing his studies in Russia and the USA on an MBA program run jointly with Taylor University. He has over 20 years’ experience in senior management roles, including 15 years as a CEO at the corporation’s various international branches. He specializes in launching start-ups in new regions and countries, and new business areas at major firms. From 1992 to 1994 he owned his own business, distributing medical equipment and pharmaceuticals. In 1995 Kirill Kaem set up a network of regional outlets for the Swedish company Oriflame in the Volga Region, which helped it become one of the region’s biggest tax-payers. In the year 2000 he began working in Germany, in the central office of the company Varta. After Varta’s merger with the American group Spectrum Brands, he spent eight years in overall charge of the company’s operations in Russia. In 2008 he relaunched the German and American holding JAFRA International in Russia, improving profit margins by 40%. In 2009 he took control of the Russian holding Hygiene Kinetics, the biggest manufacturer in the market for domestic paper and cellulose products. Within two years the company’s sales growth was several times higher than average growth in the sector, thanks to the introduction of new technologies. From 2011 to 2013 he headed up a new area of business at ‘Alpha Group’ - the biggest federal chain of clinics, ‘Alpha Health Centre’, where in the space of a year he managed to double revenue, whilst the chain itself saw profits rise by over a third. From 2013 onwards he has been a member of the Board of Directors and a co-founder of the international medical centre ‘Medcluster’, set up at the initiative of Sberbank in partnership with Strategy Group Partners, with Johns Hopkins Medicine International as a potential partner. Now Kirill is an Executive Director of BioMedical Technologies Cluster of The Skolkovo Foundation, the strategic goal of which is to concentrate international intellectual capital, thereby stimulating the development of break-through projects and technologies.

Lorenza Castellón, Business Development Consultant, Suda Ltd.

Lorenza is a health & biotech equity analyst at Equity Development Ltd. covering private & publicly listed SMEs companies in Europe and Australia. Prior to joining Equity Development in January 2005 she held similar roles at leading international investment organisations. Equity Development brings together investors and companies by means of writing and distributing detailed research. We provide the markets with both facts and opinions along with fair valuations based upon diverse and appropriate metrics. Over the last decade our brand has become synonymous with quality objective research and we have built close links with institutions across the UK and Europe; like them we are fully regulated. Our team of analysts are FSA approved and boast a cumulative 400 years of experience. Please visit www.equitydevelopment.co.uk for more details and examples of our work or contact me. I am the health & biotech analyst and I have many years of experience in the sector having worked for leading international investment organisations.



WELCOM

ESPEAKERS

t back :: next u

Speakers

Lubor Gaal, Head of Europe Search and Evaluation, Business Development, Bristol-Myers Squibb

Lubor Gaal is the Head of Europe, Search and Evaluation, Strategic Transactions Group for Bristol-Myers Squibb, based at the UK headquarters in Uxbridge (London). He is responsible for licensing and acquisition of drug programs, assets or companies in support of the company’s BioPharma strategy.

Lubor has extensive experience in evaluating and negotiating transactions with small and large companies, having worked in the U.S. and in Europe. Prior to joining Bristol-Myers Squibb, Lubor was Head of Business Development for Neuro3d in France and CBO of Vectron Therapeutics AG in Germany. In the US, Lubor worked for Berlex Laboratories, where he was responsible for worldwide licensing for Cardiovascular and Neuroscience for Schering AG. Before joining Berlex, he worked for Burrill and Company in San Francisco, where he advised biotechnology and pharmaceutical companies on business development strategies and execution. Lubor received his Ph.D. from the University of California at Berkeley and studied biology at the Universities of Mainz and Tubingen.

Marc Mansour, Chief Operating Officer & Director, Immunovaccine, Inc.

Dr Marc Mansour is an expert in molecular biology, cellular biology and applied immunology. Dr. Mansour has presented in numerous international conferences and has published in peer-reviewed journals in the areas of vaccines and cancer immunotherapy. Since he joined Immunovaccine, Dr. Mansour led the development of the DepoVax™ platform and the Company’s lead therapeutic cancer vaccine DPX-Survivac, poised for randomized phase 2 trials in ovarian cancer and glioblastoma. He continues to lead the Immunovaccine science team in evaluating the DepoVax™ platform for specific vaccine applications that are being developed in-house and with collaborators and commercial partners.

Markus Goebel, Partner, Novartis Venture Funds

Markus started his career in the Health Care Industry in 1990. An MD by training and certified, amongst others, in hematology/oncology he worked for Farmitalia Germany and later held several global positions in R&D, Marketing and Strategy at Roche headquarters, including the worldwide alliance with Amgen. He joined Novartis in 2000 and first worked as Global Head Nervous System BD&L Pharma and later as Global Head Pharma Corporate M&A. In 2004 he joined the Novartis Venture Fund as a Managing Director in the US, moving back to Europe in 2009. Previously he received an MD and a PhD from the Ludwig Maximilian’s University in Munich and an MBA from Henley Management College. Markus serves on the boards of several Novartis Venture Fund portfolio companies, having exited, amongst others from Sirtris, FoldRx, EraGen, Intellikine and LigoCyte.

Martin Welshof, CEO, Opsona Therapeutics Ltd

Martin is the CEO of Opsona Therapeutics Ltd. a leading immunology drug development company, focused on novel therapeutic approaches to key targets of the innate immune system associated with a wide range of major human diseases, including inflammatory related disease indications, such as transplant rejection and cancer. The company was founded in 2004 by three world-renowned immunologists at Trinity College in Dublin.

Before joining Opsona, Martin was the Managing Director and Co-founder of Affitech A/S, a biopharmaceutical company focused on the discovery and development of human antibodies, listed on the Nasdaq OMX Copenhagen stock exchange. Under his leadership Affitech AS was transformed through a reverse merger in 2009 with Pharmexa A/S a public Danish company and listed on the Copenhagen stock exchange. In 2010 he was one of the key resources concerning the implementation of a strategic partnership with the Russian Pharmaceutical IBC Generium as well as securing strategic investment from major Russian pharma players.

Prior to joining Affitech AS, Martin was the Director of Technology at Axaron Bioscience AG, Heidelberg, Germany in 1997 during the Company’s start-up phase. From 1999 until 2002, Martin was responsible for the R&D process related to a large portfolio of cutting-edge technologies in the field of transcription analysis and functional genomics. During this period Martin was at the parent company of Axaron Bioscience, LYNX Therapeutics Inc., Hayward, California, where he contributed to the process development of LYNX massive parallel cloning and sequencing technologies.



WELCOM

ESPEAKERS

t back :: next u

Speakers

Matthias Steger, Venture Partnering, F.Hoffmann La Roche AG

Matthias Steger is currently focusing on Venture Partnering, previously holding the position of Global Head Research & Technology Partnering at Roche.

Prior to joining Roche in his current role, Dr Steger was a Pharma/Biotech analyst at the investment bank Kepler Equities. Before that he was Head of Axovan’s orphan GPCR drug discovery platform. The biotech company was subsequently acquired by Actelion, Basel, Switzerland. He began his career in the pharmaceutical industry at Roche in 1999 as Laboratory Head in Medicinal Chemistry.

Dr. Steger holds a PhD in Medicinal Chemistry from the University of Sussex, UK, and an MBA from the University of St Gallen, Switzerland.

Michael Salzmann, COO & General Manager, Neurimmune Holding AG

Dr Michael Salzmann joined Neurimmune as COO in 2008. Dr. Salzmann held several positions in the private and public sector and he has more than 15 years of industry experience gained in Europe and Canada, especially in the areas of medtech and biotech, inter alia with Bruker and Roche. In 2005, he was appointed project director of the strategic USD 600M development venture Science City by the Swiss Federal Institute of Technology (ETH Zürich). Dr. Salzmann was awarded a PhD in biophysics in 1997 from the ETH Zürich, where he studied with Nobel Laureate Kurt Wüthrich at the Laboratory of Molecular Biology and Biophysics.

Mike Romanos, CEO, Crescendo Biologics Ltd

Mike Romanos is CEO of Crescendo Biologics. He has 25 years’ biotech and pharmaceutical industry experience in biologic and NCE drug discovery across several therapeutic areas, starting with Wellcome Biotech. Previous to his current role, Mike held global leadership positions for over 10 years in GlaxoSmithKline R&D, building and managing Discovery organisations that made a major impact in targets, technology and pipeline projects, including establishment of an advanced antibody lead discovery capability which led to a pipeline of in-house monoclonal antibodies. He is a panel member of the MRC’s Developmental Pathway Funding Scheme, which funds academic translational studies in the UK, and a Fellow of the Society of Biology. Mike holds a Natural Sciences degree from Cambridge University, and PhD in Molecular Virology from Imperial College, London.



WELCOM

ESPEAKERS

Speakers

Nicholas Franco, Executive VP, Chief Business Development Officer, Actelion Pharmaceuticals Ltd.

Nicholas Franco has over 20 years of pharmaceutical leadership andexperience in research, arketing, sales and business development across several therapeutic areas and geographies.

Prior to joining Actelion earlier this year as Executive Vice President and Chief Business Development Officer, he was Senior Vice President, International Commercial Operations at Axcan Pharma based near Paris, France where he was responsible for ex-North American operations (including Marketing, Operations and Partnering).

Prior to that, he was Head of Market Access Region Europe for Novartis Pharma AG in Basel, Switzerland, where he has held various management positions since 1991, including President of Novartis Ophthalmics, Global Head, Business Development and Licensing Negotiations, Global Head, Neuroscience Franchise and Global Brand Director for gastrointestinal products.

Education: BsC in Biochemistry and MA in Business Administration, Strategic Planning and Marketing from McGill University (Canada).

Nadine Beauger, Vice-President, Scientific Liaison, Institute for Research in Immunology and Cancer – Commercialization of Research (IRICoR)

Dr Nadine Beauger is Vice-President - Scientific Liaison (intellectual property, academia-industry relations) at the Institute of Research for Immunology and Cancer – Commercialization of Research (IRICoR), a not-for-profit drug development and commercialization center based at the Université de Montréal (UdeM) and more specifically at the Institute of Research in Immunology and Cancer (IRIC). IRICoR’s mission is to rapidly translate highly innovative and commercially promising academic projects from IRIC/UdeM and collaborating centers into high value novel therapies in oncology, immunovirology and related indications through a very flexible business model adapted to the private sector. IRICoR is one of the only fully-integrated drug discovery and commercialization centres of its kind in Canada under a single roof, with one of the largest academia-based medicinal chemistry groups in the country.

Dr. Beauger is in charge of identifying commercially promising projects for direct investment and inclusion into IRICoR’s portfolio, and advising on the most strategic intellectual property (IP) protection to generate the highest possible value from UdeM’s IP before establishment of partnerships with industry. Dr Beauger leads strategic IP portfolio management at IRICoR where she has been instrumental, since joining the organization in 2009, in developing IRICoR’s IP portfolio that currently consists of 23 patent families. IRICoR’s patent estate has contributed to the establishment of the 8 ongoing partnerships the Centre has with industry (multi-million$ in total deal value). Working in collaboration with UdeM’s upper management and its Research and Development office, Dr Beauger actively contributes to establishing agreements for upcoming collaborations.

Dr. Beauger brought to IRICoR more than 10 years of combined experience in venture capital, IP, business development and clinical research. She began her career as a Patent Consultant at Robic, a Montreal-based IP boutique, where she undertook drafting, prosecution and IP strategic management of patent applications in biotechnology for different clients including universities, spin-off companies and small biotechs.

She went on as Associate at VantagePoint Venture Partners, a leading California headquartered venture capital firm with more than $4 billion under management. She led due diligence on investment opportunities in health sciences and monitored ten of the firm’s portfolio companies. Just prior to joining IRICoR, Dr. Beauger was Manager, Business Development at Paladin Labs Inc (TSX:PLB), a top specialty pharmaceutical company based in Montreal.

She holds a Ph.D. in Biomedical Sciences (Hematology and Oncology), a M.Sc. in Cellular Biopathology from Université de Montréal and a B.Sc. in Anatomy from McGill University. She also holds an MBA degree from HEC Montréal (awarded Excellence Studentship at admission and Best Speaker award). Dr Beauger is a member of the Association of University Transfer Managers (AUTM) and of the Licensing Executive Society (LES).

t back :: next u



WELCOM

ESPEAKERS

Speakers

t back :: next u

Oliver Middendorp, Co-CEO & CBO, Numab AG

Oliver Middendorp is the CBO and co-CEO, as well as a founder of Numab. Prior to this role, he served as Head of Alliance Management at Esbatech. In this function Oliver negotiated and concluded various collaboration and license agreements and managed the resulting alliances. Furthermore, he was responsible for managing Esbatech’s patent portfolio, as well as for analyzing Esbatech’s freedom to operate. After Esbatech was acquired by Alcon in September 2009, Oliver took over additional responsibilities in Alcon’s R&D Alliance Group, where he became responsible for search, evaluation, negotiations and alliance management of collaborations in the fields of external diseases and drug delivery. Oliver studied molecular biology and immunology at the University of Zurich and received his PhD in biochemistry from the University of Basel in 2004. In the same year he was offered the position as Esbatech’s business developer and became a member of the Esbatech Management.

Pawel Przewiezlikowski, CEO, Selvita

Pawel co-founded Selvita in 2007 and is the Chief Executive Officer of the company, responsible for strategic management, business and corporate development. He is also the Chief Executive of BioCentrum, Selvita’s daughter company. Mr. Przewiezlikowski is a member of the Economic Council of the Malopolska (Krakow) region as well as of the Malopolska Innovation Council. From 1994 to 2007 he worked at Comarch, a Polish information technology company. As a management board member since 1996, he was responsible for the divisions offering solutions for the pharmaceutical, banking, manufacturing and services industries and took part in the organic transformation of a university spin-off to the largest organically grown IT company in Central and Eastern Europe, employing over 2 700 people in 20 countries. During his time at Comarch in 1999-2000 he was also the co-founder and the first CEO of Interia.pl, the third largest portal in Poland. Mr. Przewiezlikowski holds an MBA from the joint program of the University of Teesside (United Kingdom) and Krakow School of Economics (Poland) as well as master degree in computer science from AGH Technical University in Krakow. He also studied IT at the Technical University in Berlin.

Pascal Touchon, Director of Scientific Cooperation & Business Development, Servier

Pascal Touchon has 26 years’ experience in the pharmaceutical industry in Research, Marketing and Sales, General Management and Business Development.

He has extensive international experience in managing commercial operations and as CEO in France, Central & Eastern Europe, Northern Europe, Asia, Australia, Canada, and South Africa.

As head of Business Development for Servier over the last 3 years, he led the closing of more than 18 partnerships with biotech companies and academic institutes, managed various existing alliances and conducted two company acquisitions.

Servier is a private research based pharmaceutical company with sales of 3.9 billion euros worldwide and activities in cardiovascular diseases, type II diabetes, neurology, psychiatry, rheumatology and oncology.

Pascal holds a Doctorate in Veterinary Medicine, a DESS in Management and an MBA from INSEAD.

Philippe Calais, CEO, Isarna Therapeutics

Philippe joined as Chief Executive Officer on March 1, 2012. He has over 25 years of biopharmaceutical and pharmaceutical industry experience in both North America and Europe. Formerly he was the President and CEO of Univalor, one of the largest technology transfer organizations in North America, located in Montreal, Canada. He has managed biopharmaceutical companies in Canada and served as a consultant to life science companies, focusing on corporate strategic positioning, company deployment and sales optimization strategies. His management expertise, combined with extensive experience with large pharmaceutical companies such as ICI Pharmaceuticals and Roche, covers the full scope of the drug chain – from discovery to clinical development, commercialization as well as partnership and franchise strategic marketing for several therapeutic areas. He has a degree and doctorate in pharmacy from the U. F. Rabelais, Tours, France. AGH Technical University in Krakow. He also studied IT at the Technical University in Berlin.



WELCOM

ESPEAKERS

t back :: next u

Speakers

Ralph Villiger, Managing Partner, Avance

Ralph Villiger studied mathematics and finance and holds degrees from the Swiss institute of technology Lausanne (EPFL) and Oxford University.

Ralph is managing partner at Avance, a globally renowned valuation specialist for pharma and biotech. Avance specialises in financial deal structuring (license contracts, M&A, fund raising, new business models). He authored the book “Valuation in Life Sciences. A Practical Guide” and is a regular speaker at conferences and various universities.

Since 2011 Ralph is also managing partner of Sixth Element Capital, which runs the CRT Pioneer fund (development of oncology assets). Ralph is a passionate single-handed sailor and mountaineer and has a special interest in wine.

Rainer Henning, Chief Executive Officer, Biomay AG

Rainer Henning serves as Chief Executive Officer of Biomay AG since January 2011. He looks back on a distinguished career of over 30 years in the biotechnology, pharmaceutical and venture capital industry. Before joining Biomay, he was Chief Executive Officer of Fibrex Medical, Inc., a biopharmaceutical company in the field of critical care medicine, a position he took over after working as investment manager and partner of two European venture capital funds for several years. His experience in the pharmaceutical industry encompasses operational and senior executive R&D positions in Hoechst AG, Hoechst Marion Roussel and Aventis. A chemist by training, he is inventor of over 80 granted patents, which cover among others the blockbuster antihypertensive ramipril. In addition, he has advised and served on the board of a number of biotechnology companies.

Regina Hodits, General Partner, Wellington Partner Life Science Venture Capital Consulting GmbH

Regina joined Wellington Partners in spring 2010 as a part-time advisor and stepped up to General Partner in January 2011. Since 2000, she has become an influential investor in the European venture capital industry, focusing on early-stage and growth deals in Life Sciences. Her industry experience and her strong scientific background will help the Wellington Life Sciences team to strengthen its position in the European investment market. She is currently representing Wellington Partners on the Boards or Atopix, Ayoxxa, MiddlePeak Medical and Sapiens Neuro.

Until January 2010, Regina led the life sciences efforts of Atlas Venture in Europe, a leading transatlantic venture capital firm. As a Partner at Atlas Venture, she led numerous financing rounds and was the founding investor in Bicycle Therapeutics, Fibrex, F-star and Jenavalve. In addition, she served on the Board of Egalet, Lumavita, Novamed and Protaffin and is an external director at GlaxoSmithKline’s (GSK) Respiratory CEDD. Regina was also on the Board of U3 Pharma, which was acquired by Daiichi Sankyo Co.,Ltd. in 2008.

From 2000 to 2004, while working for Apax Partners, she was responsible for healthcare investments in Germany and was closely involved in investments such as Genmab, Silence Therapeutics and Wilex. She started to build her extensive network in the global healthcare industry during her tenure at McKinsey from 1997 to 2000.

In the 90s, Regina gained profound insights into the fast-growing biotech sector as university lecturer and post-doctoral researcher at the University of Vienna and the MRC Cambridge, where she collaborated extensively with emerging UK biotech companies.

Regina studied chemical engineering in Vienna and holds a Ph.D. in biochemistry.

Richard Godfrey, CEO, BerGenBio AS

Richard joined BerGenBio as Chief Executive Officer in 2008. He has more than 25 years industry experience leading many international drug development and commercialization partnerships. Formerly he served as Chief Executive Officer of Aenova Inc., a specialist biopharmaceutical company. Prior to this he was the Managing Director of DCC Healthcare Ltd and previously he held positions of increasing responsibility at Catalant, Eli Lilly and Reckitt Benckiser in R&D and commercial roles. He qualified as a Pharmacist from Liverpool University and received his M.B.A. from Bath University.



WELCOM

ESPEAKERS

t back :: next u

Speakers

Richard Goodfellow, Joint CEO, Scancell Holdings Plc.

Richard has had many yearsin the pharmaceutical industry, in both Big Pharma and with Biotech companies. During his time at Astra, he oversaw the launch of Losec and other key products internationally. Thereafter, he held the post of Director of Licensing and New Business Development at Scotia Pharmaceuticals, where he was involved with the company’s flotation on the London Stock Exchange and successfully negotiated numerous deals. Dr Goodfellow is also a founder of Paradigm Therapeutics, a Cambridge based functional genomics company and is a former Director of Enact Pharma plc. He is currently co-founder and Joint CEO of Scancell Holdings plc. He qualified as a Pharmacist from Liverpool University and received his M.B.A. from Bath University.

Roel Schaapveld, CEO, InteRNA Technologies BV

Roel joined InteRNA Technologies as the first employee in February 2008 as Chief Operating Officer and was named Chief Executive Officer in May 2009 to manage the company’s day-to-day operations and to develop the company’s strategy and opportunities for further development. Prior to InteRNA he was senior manager in the corporate finance biotech team at Dutch merchant bank Kempen & Co.

Previously, he held several positions at KREATECH Biotechnology, among which VP Corporate and Business Development. Roel holds a M.Sc. in Molecular Biology and received his Ph.D. from the University of Nijmegen, the Netherlands. During his academic career he worked at the Roche Institute for Molecular Biology (Nutley, NJ), the Dana-Farber Cancer Institute (Boston, MA) and at the Netherlands Cancer Institute in Amsterdam. Roel received his MBA from Nyenrode Business School, The Netherlands.

Ron Laufer, Senior Managing Director, Medimmune Ventures

Ron Laufer is the head and Senior Managing Director of MedImmune Ventures, a $400M evergreen venture capital fund, which is a subsidiary of the AstraZeneca Group.

An experienced healthcare investor, Ron started his career as a physician before moving into venture capital. He was a co-founder of Lilly Ventures, the venture capital arm of Eli Lilly & Company, and later a managing director at Visium Asset Management, a healthcare-focused investment firm, before joining MedImmune Ventures in April of 2010.

Ron received his B.Sci., M.D. and M.P.H. from Hebrew University, and an M.B.A. from the Harvard Business School. He is currently an adjunct Professor of business administration at the Kelley Business School.

Ronen Kahana, CEO, BMR Solutions Ltd.

Ronen is Co-founder and CEO of BMR Solutions Ltd - a pharmaceutical startup company engaged in the development of immunostimulants and cancer supportive care drugs. Mr. Kahana holds M.Sc. in industrial biotechnology from Bar-Ilan University, Ramat Gan, Israel. In 2004 Mr. Kahana has founded AVA Biodefender Ltd for the development of anti-viral solutions and served as a CTO, director and board member until 2011. Mr. Kahana has broad experience in the development of vaccines; he worked at the Israeli veterinary laboratory for vaccine control at KVI (Kimron Veterinary Institute) on development and implementation of new technologies. In addition, Mr. Kahana is doing pro-bono consulting to several young Israeli startup companies at early stages, participates in educational activities for new entrepreneurs. In addition Mr. Kahana tutoring EMBA program students and giving guest lectures at graduate school of business management at Bar Ilan and Haifa universities.



WELCOM

ESPEAKERS

t back :: next u

Speakers

Sara Nunez-Garcia, Associate in Life Sciences, Sofinnova Partners

Sara joined the Life Sciences team at Sofinnova Partners as an Associate in 2013; she focuses on investments in the biopharmaceutical sector. Prior to Sofinnova, Sara worked in the Licensing and M&A team at Onyx Pharmaceuticals in California, where she proposed option-based and structured deals for various potential acquisitions in the oncology space.

Previously, Sara spent six years in the pharmaceutical industry with Solvay Pharmaceuticals and Abbott Laboratories in The Netherlands as a Medicinal Chemist. During her time in drug discovery, Sara worked on preclinical programmes for central nervous system indications, contributing to the submission of several IND packages of novel chemical entities. In addition, Sara led transfer-of-knowledge projects with several universities in Amsterdam.

Sara was a postdoctoral fellow in the Biochemistry and Biophysics departments at the Albert Einstein College of Medicine in New York where she developed inhibitors for oncology targets. She has a PhD in Chemistry from the University of Manchester; her doctoral research used a combination of experimental and computational techniques to design and synthesize transition state inhibitors for various enzymes. Sara has published eighteen peer-reviewed articles and patents. Sara also holds a full-time MBA (major in finance) from INSEAD.

Stephanie Léouzon, Principal and Head of Torreya Partners Europe, Torreya Partners (Europe) LLC

Stephanie Léouzon is Partner and Head of Europe for Torreya Partners, a life sciences boutique advisory firm which she joined in 2012. She also serves on the Board of Directors of Immunovaccine Inc. Previously she worked in Health Care Investment Banking in the US and Europe from 1989-2010, most recently at Credit Suisse as a Managing Director and Senior Advisor. She has advised life sciences clients on more than 20 strategic transactions, valued at over $65billion, and been involved in over 45financing transactions to provide over $10 billion to health care clients.

Stephanie earned an M.B.A. degree from the Darden Graduate School of Business at the University of Virginia in 1989 and a B.A. degree, cum laude, from Mount Holyoke College in 1985.

Tim Haines, Partner, Abingworth LLP

Tim Haines a Partner at Abingworth LLP has more than 25 years of international management experience in the life sciences industry. Before joining Abingworth in 2005 he was Chief Executive of the Abingworth portfolio company, Astex Therapeutics. Tim was with Astex for more than five years and was instrumental in establishing it as one of the leading UK biotechnology companies. Previously, Tim was Chief Executive of two divisions of the publicly-listed medical technology company, Datascope Corp. Prior to Datascope, he held a number of other senior management positions in the US and Europe, including CEO of Thackray Inc and General Manager Baxter UK. Current and past board positions include Astex Therapeutics (ASTX: NASDAQ), Chroma, Fovea (Acquired by Sanofi Aventis), HBI (acquired by Meda), Pixium Vision, PowderMed (Acquired by Pfizer), KSpine, Stanmore Implants, Lombard Medical (AIM) and XCounter (AIM). Tim has a BSc from Exeter University and an MBA from INSEAD and is a former Director of the Biotech Industry Association and currently sits on Venture Committee of the British Venture Capital Association.

Thomas Hegendörfer, Head of Business Development, Lead Discovery Center GmbH

Thomas Hegendörfer is in charge of Business Development at the Lead Discovery Center (LDC) where he is involved in evaluating early therapeutic projects as well as outlicensing assets to and managing LDC’s partnerships with the Pharma industry. Before joining the LDC he worked at Max-Planck-Innovation in Technology Transfer. Together with Dr. Matthias Stein-Gerlach he developed the business model of a Max-Planck Drug Discovery Center from business plan to operational set-up of the LDC and subsequently joined the LDC in 2008. In previous positions he worked for Cancer Research UK and the GSF Munich in academic research. He graduated in Molecular Medicine from Imperial College, London, and holds a degree in Molecular Biotechnology from the Technical University of Munich.



WELCOM

ESPEAKERS

Speakers

t back :: next u

Thomas Kronbach, CEO, BioCrea

Thomas is CEO of BioCrea, which he established as a Management buy-out of assets from Biotie Therapies Corp. in 2010. A new Management Team and new scientific and business ideas were combined with a productive CNS-discovery group. The first success was the acquisition of BioCrea’s Cognition Program by Boehringer Ingelheim in 2012. Since then new projects for Epilepsy, Autism, Depression and Huntington’s disease were established.

Tom has initiated and fostered partnerships with Boehringer Ingelheim, Wyeth/Pfizer and GlaxoSmithKline. Previously, Tom was the CSO of Biotie Therapies Corp. and CSO and co-founder of elbion AG.

Tom holds a Ph.D. in Chemistry from the University of Tubingen, Germany. He was a Post Doctoral Fellow with Urs A. Meyer in Pharmacology at the University of Basle, Switzerland and was Research Associate in Molecular and Experimental Medicine with Eric F. Johnson in at The Scripps Clinic and Research Foundation in La Jolla, CA. Tom then joined Goedecke-Parke Davis in Freiburg, Germany and then Asta Medica -AWD, a Degussa company in Radebeul, Germany, where he had increasing responsibilities up to being Head of R&D.

Ulrich Jahnel, SVP Global Preclinical R&D, Grünenthal GmbH

Ulrich is responsible for all preclinical projects and technical development activities within Grünenthal. He is covering the scientific aspects of new chemical entities - from discovery stage until registration. As nonclinical representative within cross-functional project and portfolio boards, he takes responsibility for stage gate and portfolio decisions, budget assignment and capacity allocation. Within his 20+years in pharma R&D, he has been involved in international product developments and launch teams, networking events as well as strategic and organizational tasks and challenges.

Vincent Charlon, CEO, Anergis

Vincent joined Anergis in January 2009 as Chief Executive Officer (CEO). Dr Charlon brings over 20 years of global clinical development and management experience. From 1990 to 1998, at Hoffmann La Roche Basel as Clinical Research Scientist and then at Hoffmann La Roche Inc. Nutley,USA, as Director of Clinical Research, Dr Charlon held clinical development responsibilities for several international projects. He was the first author of an approved global new drug application for an anti-antihypertensive and anti-anginal new chemical entity and was involved in numerous meetings with the US FDA and European regulatory authorities. From 1998 to 2006, Vincent Charlon was CEO of Hesperion Ltd., the contract research organization (CRO) who designed and conducted all initial clinical trials for Actelion’s [SWX, ATLN] products. In this capacity, Vincent Charlon designed the first clinical trials of Tracleer® in pulmonary hypertension, today Actelion’s biggest product with sales well over CHF 1 billion/year. Vincent Charlon developed Hesperion as a profitable CRO from 3 to 200 employees located in eight country offices, serving over a hundred clients. Two third of Hesperion clients were small biotech companies from North America and Europe. During that time, Dr Charlon also realized two company acquisitions and integrations into Hesperion, as well as the sale of Hesperion to Cerep SA. In 2007-2008, Vincent Charlon was CEO of the drug repositioning start-up company LS Pharma International SA before joining Anergis.

Wilder Fulford, Principal, Torreya Partners (Europe) LLC

Wilder is the founding partner of Torreya Partners Europe, the London branch of Torreya Partners, an international advisory firm assisting Life Science companies with M&A, licensing, alliances, financings and other transactions. Dr. Fulford has had a long career advising healthcare companies of all kinds around the globe. After completing his PhD in molecular biology at the Rockefeller University in 1986, he worked for a few years as a venture capitalist, before embarking on a career as an M&A advisor. He has run healthcare M&A or coverage groups in New York and London at Salomon Brothers, Merrill Lynch, Bank of America and (most recently) Deutsche Bank. He has participated in close to 100 financing and M&A transactions with an aggregate value in excess of $100 billion. Torreya Partners has a full team in London, and about a dozen mandates in execution, and has closed five transactions so far in 2013 in biotechnology, specialty pharma, vaccines, medical devices, and OTC. Globally, Torreya Partners has completed over 100 Life Sciences assignments in the 6 years since inception.

SUPPORTING ORGANISATIONSPRESENTING COM

PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

Ability Pharmaceuticals www.abilitypharma.com

CONTACTCarles Domènech, PhDChief Executive Officer

ADDRESS Edifici Eureka – Campus de la UAB 08193 Bellaterra (Barcelona) Catalonia Spain

TELEPHONE + 34 93 586 8977

EMAIL [email protected]

YEAR FOUNDED2009

COMPANY PROFILE

Ability Pharmaceuticals, SL has its first drug candidate ABTL0812 in Phase I/Ib clinical trials in cancer patients with advanced solid tumors, with enrichment in lung and pancreatic cancer. The first administration to the first patient has been in February 24, 2014.

The company is developing a patented new drugs class called Lipid Analogue Therapeutics, which is highly differentiated and has an innovative mechanism of action, with action on several targets. ABTL1014, which is expected to start preclinical development in spring 2013.

ABTL0812 is an antiproliferative and cytotoxic drug with a novel mechanism of action (MoA). It was selected for preclinical development because, a) its activity over a wide panel of tumor cell lines (lung, pancreatic, lymphatic, liver, melanoma and glioma, breast, neuroblastoma); b) its good efficacy in animal models of cancer; c) its low in vivo toxicity; and d) once dayly oral administration. Importantly, it shows synergistic properties with standard of care (SOC) drugs such as docetaxel and gemcitabine. It is also active on cells resistant to cis-platin, lapatinib and trastuzumab.

ABTL0812 affects two major cell processes related with cellular division, and thereby with proliferation of tumor cells: a) inhibition of the mTORC1 and mTORC2 pathways, and b) DNA synthesis through the inhibition of dihydrofolate reductase (DHFR) gene expression. The modulation of these main cellular functions induces cell death by autophagy, a mechanism of self-digestion of the cell.

A second candidate ABTL1014, is currently in preclinical development.

MANAGEMENT Carles Domènech, PhD, Chief Executive Officer - Co-founder. PhD in Cell Biology & Business Training. Previously 13 yrs in BDL at Almirall & Lacer. 2.5 yrs in biotech venture capital (Barcelona Emprèn and CIDEM). 8 yrs in science research, incl.2 yrs at Memorial Sloan-Kettering Cancer Center (New York). BS/MS Biology.

José Alfón, PhD, VP Research & Development Previously 12 yrs. Team leader drug development and dsicovery (at the biotech Palau Pharma and Uriach). PhD in Pharmacology, Research at Hebrew Univ. of Jerusalem and Universitat de Barcelona. BS/MS Pharmacology.

Vanessa Ruz, Director, Finance & Administration . Prior to Ability pharma years she was the Chief Financial Officer of Sevibe Cells, SL. BEc/MEc in Economics.


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

Affimed Therapeutics AG www.affimed.com

CONTACTSDoris Sommer

Claudia Heisch

ADDRESS Affimed Therapeutics AG Technologiepark, Im Neuenheimer Feld 582 D - 69120 Heidelberg Germany

TELEPHONE +49 6221 65307 0

FAX +49 6221 65307 77

EMAIL [email protected] [email protected] [email protected]

YEAR FOUNDED2000

FINANCIAL SUMMARY

Investors: Orbimed • Aeris • LSP • BioMed Invest • Novo Nordisk A/S

COMPANY PROFILE

Affimed is a clinical stage company developing bispecific TandAb® antibodies in oncology. TandAbs engage T cells or NK cells enabling potent killing of tumor cells. The lead product AFM13, directed against CD30 and CD16A, has been investigated in Phase 1 trial in Hodgkin’s lymphoma patients. The product was safe and well tolerated and showed clinical efficacy in patients. Phase 2a has been initiated. A second program, AFM11 which is targeting CD19 and CD3, is developed for the treatment of NHL and ALL. Phase 1 has been initiated. TandAbs® possess increased therapeutic potential compared to monoclonal antibodies or other antibody fragments. They have drug-like properties with excellent product stability. A robust manufacturing process has been established. Affimed recently entered into a partnership with Janssen on the development of a novel TandAb molecule through its subsidiary Amphivena. Affimed is backed by a peer group of investors including Orbimed, Aeris, LSP, BioMed Invest and Novo Nordisk A/S. Affimed has collaborations with Janssen and the Leukemia and Lymphoma society.

MANAGEMENTDr Adi Hoess, CEODr Eugene Zhukovsky, CSODr Florian Fischer, CFODr Jens-Peter Marschner, CMODr Uli Grau, Advisor


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

AIDDwww.aidd.ch

CONTACTChris Maggos Business Development

ADDRESS Lausanne, Switzerland

TELEPHONE +41 79 367 6254


YEAR FOUNDED2013

FINANCIAL SUMMARY

Currently supported by its founders, AIDD is seeking startup financing

COMPANY PROFILE

The Alpine Institute for Drug Discovery (AIDD) is focused on immunotherapeutics for oncology, autoimmune and inflammatory diseases. Pilot discovery projects include differentiated novel treatments for validated therapeutic targets with high potential for treatment of prostate cancer and irritable bowel disease.

AIDD founders have track records in translating novel biology into small molecule or antibody pre-medicines, as well as in managing and leveraging the related intellectual property. The AIDD team has exceptional expertise in allosteric modulator discovery and development.

AIDD is fostering relationships with leading research institutions and expects to initiate the majority of its projects via public private partnerships – further increasing AIDD’s capital efficiency. To encourage new dialogues around exciting targets, AIDD makes its technology suite available to assist academic partners with target identification, characterization and validation efforts. Through collaborations bridging academia and industry, AIDD will become a partner of choice for translational discovery and a stable, trusted provider of high-quality pre-medicines (i.e. lead compounds) for pharmaceutical partners and venture investors.

AIDD will seek to drive projects from assay design through to the final stages of lead optimization, such that molecules achieve preclinical validation and demonstrate high potential ADMET profiles. Individual projects are expected to take three to five years and cost $3-5 million per project, depending on the complexity. Each project will become a new company (partially owned by AIDD) and/or be licensed to pharmaceutical partner(s) who have the infrastructure and competencies for clinical development, regulatory, sales & marketing.

MANAGEMENT

Laurent Galibert, Scientific StrategyThibaut De Smedt, BiologyBenjamin Perry, ChemistryChris Maggos, Business Development


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

Altermune Technologies www.altermune.com

CONTACTSMike Westby CEO

Charles Roberts Chairman

ADDRESS 2876 Michelle Drive Suite 300, Irvine CA, 92606

TELEPHONE +44 (0)203 397 8861

EMAIL [email protected] [email protected]

YEAR FOUNDED2010

FINANCIAL SUMMARY

Total previously invested: $6,000,000

COMPANY PROFILE

Altermune is a preclinical stage therapeutics company developing a proprietary platform technology, the brainchild of Nobel Laureate Dr Kary Mullis (inventor of PCR). Our technology addresses significant unmet medical need in infectious diseases.

Altermune’s technology employs a process we call ‘programmable immunity’ whereby pre-existing antibodies can be re-directed to a target of our selection with the use of molecules termed ‘Alphamers’.

Alphamers consist of targeting and recruitment modalities. The targeting portion consists of a structured oligonucleotide (aptamer), which exhibits extreme specificity for its target, and an oligosaccharide which redirects natural and potent antibodies to fight infection. Alphamers exploit an entirely new selective mechanism of action when compared to existing anti-infective therapeutics.

Altermune’s CEO has over fifteen years Pharma experience (Pfizer, Roche) and played a major part in developing an approved first-in-class antiviral therapy, Selzentry™ .

Altermune’s Discovery lead is highly experienced in the therapeutic aptamer field having held roles at Archemix and Baxter. Our laboratory is in Austin Texas, and we have several collaborations with world-renowned academics.

MANAGEMENT

Dr Mike Westby, CEO Dr Charles Roberts, Chairman Dr Paul Hatala, Head of Discovery


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

Amal Therapeutics SA www.amaltherapeutics.com

CONTACTMadiha Derouazi CEO

ADDRESS Amal Therapeutics SA c/o Fondation pour Recherches Médicales 64 av. de la Roseraie 1205 Geneva

TELEPHONE +41 79 394 94 47

EMAIL Madiha.derouazi @amaltherapeutics.com

YEAR FOUNDED2012

FINANCIAL SUMMARY

Seed Round Closed

COMPANY PROFILE

Amal Therapeutics SA is a privately-held Swiss biotech start-up company and a spin-off from the University of Geneva. Amal was incorporated on September 3rd, 2012. Its main objective is to develop and progress a novel therapeutic cancer vaccine using proprietary vectors fused to rationally designed multi-epitopic cargo.

MANAGEMENT

Madiha Derouazi, CEOMadiha Derouazi holds a PhD in Biotechnology from the EPFL, Switzerland and a Master in Biotechnology Engineering from the University of Technology of Berlin, Germany. Madiha Derouazi has been working on vector engineering and therapeutic cancer vaccines for over 9 years.


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

Anaconda Pharma www.anacondapharma.com

CONTACTMarta Blumenfeld CEO

ADDRESS 1 mail du Prof. Georges Mathé Villejuif Biopark 94800 VILLEJUIF FRANCE

TELEPHONE + 33 1 82 28 73 02

FAX + 33 1 82 28 73 01

EMAIL mblumenfeld @anacondapharma.com

YEAR FOUNDED2003

FINANCIAL SUMMARY

Private ownership

Founders/Institut Pasteur/Private Investors

COMPANY PROFILE

Anaconda Pharma (www.anacondapharma.com) is a clinical stage biopharmaceutical company focused on the development of treatments against infections by Human Papillomavirus (HPV). The company is a spin-out from Institute Pasteur and based out of Paris. Its scientific advisory board comprises some of the leading scientists in the field of HPV and related diseases.

Anaconda Pharma was established to develop innovative antiviral drugs that function by disrupting protein-protein interactions.

Anaconda’s lead compound AP611074 is a first-in-class, patented NCE that has been shown to be safe and effective in removing or reducing condyloma (ano-genital warts) in a double-blinded, placebo-controlled, randomized Phase IIa clinical study completed in July 2013.

Ano-genital warts (condyloma) have a global prevalence in the sexually active population of about 1% (millions of new cases per year in mature markets alone), and are much more frequent in immune-compromised patients. While not life-threatening or debilitating, condyloma is mostly perceived by affected individuals as a disfiguring and shameful condition, causing anxiety and severe social and psychological stress. Patients typically have several episodes during lifetime. Current treatments are painful, have frequent local side effects, can result in scarring, and have low efficacy and high relapse rates.

Ano-genital warts are caused by HPV 6 and 11. AP611074 is an inhibitor of the interaction of E1 and E2 proteins of HPV6 and 11. It is the first and only drug candidate designed to block HPV replication that is in clinical development. AP611074 has an excellent safety profile as demonstrated in both pre-clinical and clinical testing.

AP611074 can also be utilized to address Recurrent Respiratory Papillomatosis (RRP) – an orphan indication that affects between 1 and 7 persons in 100’000 (both infants and adults. In addition to the topical form under clinical development, AP611074 can be formulated for oral delivery, e.g. to address RRP or to treat cases of widespread condyloma (e.g. for immune-compromised patients, as HIV+ or transplanted patients).

Anaconda’s proprietary discovery knowhow can also be applied to search for inhibitors of other HPV subtypes, notably those causing common warts and cervical dysplasia or cancer.

MANAGEMENT

Marta Blumenfeld, CEOIsmahane Bali, CFODelphine Compere, ChemistryPatricia Françon, Biology


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

Anergis www.anergis.ch

CONTACTSVincent Charlon PhD CEO

Zoltan Czigler MBA, CFO

ADDRESS BioPole III Route de la Corniche 9B CH-1066 Epalinges Switzerland

TELEPHONE +41 21 651 9220

FAX +41 21 651 9221


YEAR FOUNDED2001

FINANCIAL SUMMARY

CHF 30M funding received from venture capital and private investors

COMPANY PROFILE

Anergis SA is a Swiss-based biopharmaceutical company specializing in the discovery and development of novel allergy vaccines targeting the most frequent allergies. Anergis´ vaccines are based on its proprietary Continuous Overlapping Peptides (“COP”) technology. Allergies are the most prevalent and the fastest growing chronic conditions in the industrialized world, with over 500 million people affected.

Anergis’ lead-product AllerT, a vaccine to treat birch pollen allergy, recently completed Phase II clinical development. AllerR, its vaccine candidate for the treatment of patients with allergy to ragweed pollen has received positive feedback from the U.S. FDA for the final preclinical and early clinical program and AllerDM, Anergis’ vaccine candidate for patients with house dust mite allergy, is progressing through preclinical development. Anergis has raised over CHF 30 million from Renaissance PME-Vinci Capital, Sunstone Capital, BioMedInvest and other investors including Esperante Ventures and Defi Gestion.

Anergis COPs reproduce the full-length amino acid sequence of the allergen in separate long peptides. COPs do not cross-react with IgE, the antibody class responsible for eliciting allergic hypersensitivity. Therefore, COPs can be safely administered at high doses to induce tolerance to the allergen after few injections only. Studies of COPs in vitro, in animals and in humans have confirmed the safety (no immediate allergic reaction) and immunogenicity (production of specific IgG4 antibodies and cytokines against the original allergen) of ANERGIS COPs. In a Phase I/IIA trial with AllerT, a trend for symptom improvement was observed during the season and long term follow-ups of the same patients demonstrated that antibodies against the birch pollen major allergen bet v 1 were still significantly elevated in comparison with placebo-treated patients, two and four seasons after the very short one-time preseasonal treatment (5 SC injections in 2 months) with AllerT.

A large 240-patient, double-blind, placebo-controlled, randomized, multicentre European trial was completed in summer 2013. Based on these results (not yet disclosed at the time of this summary), Anergis will now proceed to Phase III, either with a pharmaceutical partner or supported by a round B of financing with current and new investors.

MANAGEMENT

Vincent Charlon, PhD, CEOChristophe Reymond, PhD, CSOZoltan Czigler, MBA, CFOFrançois Spertini, MD, Allergy Expert, FounderGilles Della Corte, MD, Clinical DevelopmentEva Castagnetti, PhD, Product DevelopmentGerard Farmer, PhD, Regulatory AffairsJean Paul Rohmer, PhD, Business Development


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

Asceneuron www.asceneuron.com

CONTACTDirk Beher, PhD Chief Scientific Officer & Founder

ADDRESS EPFL Innovation Park Bâtiment B CH-1015 Lausanne Switzerland

TELEPHONE +41 21 693 8242

FAX +41 21 693 8247


YEAR FOUNDED2012

FINANCIAL SUMMARY

Asceneuron SA has raised to date EUR 5M seed funding from Merck Serono Ventures.

COMPANY PROFILE

The Company Asceneuron was formed in Octo-ber 2012 through the spin-off of Merck Serono’s Alzheimer’s dis-ease drug discovery portfolio and research group. Asceneuron develops disease-modifying therapeutics for orphan tauopathies and improved symptomatic drugs for Alzheimer’s disease.

Asceneuron Pipeline Our O-GlcNAcase inhibitor prevents the removal of O-linked beta-N-acetyl-glucosamine carbohydrate moieties from the microtubule-associated tau protein. Thereby the formation of toxic neurofibrillary tangles in the brain can be drastically reduced. Our current clinical candidate is expected to enter Phase I studies in 2015. The M1 muscarinic acetylcholine receptor positive allosteric modulator (M1 PAM) is aimed at improving cognitive function by stimulating cholinergic neuro-transmission. This approach exploits a biological pathway which has yielded acetylcholinesterase inhibitor drugs and aims to achieve greater efficacy.

Our Business Model Asceneuron’s approach is the enhancement of the value of our preclinical assets by progressing them to clinical testing for orphan tauopathies and Alzheimer’s disease.

Our unbiased approach allows us to capitalize on the renewed interest for improved symptomatic Alzheimer’s disease treatments and in addition to take advantage of the increased industry focus on tau and orphan drugs.

We view our O-GlcNAcase inhibitor and M1 PAM programs as highly competitive with First in Class potential. Both programs address high unmet needs whilst Asceneuron has made major strategic efforts to substantially de-risk their clinical development.

MANAGEMENT

Dirk Beher (PhD), Chief Scientific OfficerDirk Beher is a founder of Asceneuron SA and joined the company as Chief Scientific Officer. He led the spin-off proposal for Merck Serono’s Alzheimer’s disease portfolio and successfully raised EUR 5M seed funding which materialized in the creation of Asceneuron SA in October 2012. Dirk has more than 22 years of experience in the field of Alzheimer’s disease and spent over 16 years in pharmaceutical drug discovery and biotech.

Previously, Dirk was the director of the Neurobiology Unit at Merck Serono in Geneva, Switzerland. He was responsible for the strategic build-up of Alzheimer’s disease as a new indication and implemented the projects which represent Asceneuron’s pipeline.

Prior to Merck Serono Dirk worked in the Neuroscience Department at Amgen Inc. in Thousand Oaks, California where he oversaw a diverse CNS portfolio as management team member. Dirk started in pharmaceutical drug discovery by joining Merck Sharp & Dohme in Harlow, United Kingdom in 1998. During that time he made key contributions to the g-secretase inhibitor MK 0752 and was finally responsible for all g-secretase programs.

Dirk holds a Ph.D. and a Diploma (M.S.) in Biology from the Ruprecht-Karls University Heidelberg, Germany. He is an inventor of seven patents and currently authors 49 peer-reviewed publications and reviews.

Christoph Wiessner (PhD), Head of DiscoveryChristoph Wiessner is a founder of Asceneuron and Head of Discovery of the company. Previously he was a director in the Therapeutic Area “Neurodegenerative Diseases” at Merck Serono (2008-2012), and headed the CNS Target and Lead Discovery Unit at Novartis in Basel (1996-2008). There he also led the drug discovery team for CAD106, a vaccine for Alzheimer’s Disease currently in Phase II, and contributed to several CNS projects that entered into clinical testing. He obtained his PhD in the department of Nobel laureate Hartmut Michel at the MPI for Biophysics, Frankfurt, Germany. He then joined the department of Konstantin-Alexander Hossmann at the MPI for Neurological Research, Cologne, Germany, and concluded this work with a habilitation in Experimental Neurology at the Medical Faculty of the University of Cologne. He authored 59 peer-reviewed publications and book chapters.


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

BerGenBio AS www.bergenbio.com

CONTACTMr Richard GodfreyChief Executive Officer

ADDRESS BerGenBio AS Jonas Lies vei 91 5009, Bergen, Norway

TELEPHONE +47 917 86 304

EMAIL [email protected] [email protected] [email protected] [email protected]

YEAR FOUNDED2008

FINANCIAL SUMMARY

Private Company Funding history: – Series A $9m Dec 2011

– Series B $6m May 2013 – Series C $12.5mJan 2014

Investors: – Norwegian syndicate Funding Plan: – TBA

COMPANY PROFILE

BerGenBio is a clinical stage biopharmaceutical company focused on the development of first-in-class treatments for aggressive, drug resistant cancers. The Company is a world leader in understanding epithelial-mesenchymal transition (EMT) biology, which is widely recognized as a key pathway in cancer drug-resistance and metastasis. Building on this original biological insight BerGenBio is developing a promising pipeline of novel EMT inhibitors.

BerGenBio were among the first to recognise the Axl receptor as an important drug target in aggressive cancers. Axl receptor tyrosine kinase is a key enzyme involved in the EMT pathway and is widely associated with acquired drug resistance. Available data shows that blocking Axl reduces and reverses cancer drug resistance and prolongs survival in animal models of many cancers.

Pipeline BGB324, is the first highly selective Axl kinase inhibitor in clinical development. It recently completed a phase Ia clinical trial to access safety, pharmacokinetics and tolerability. Phase Ib trials in 2014 will explore the use of the drug in acute myeloid leukemia (AML) and Tarceva-resistant non-small cell lung cancer (NSCLC).

AXL Companion Dx, the Company has target IP and has developed proprietary assays for patient segmentation and Pharmaco-dynamic profiling during clinical trials.

BGB001 a series of multi format Axl mAb, Lead-op stage.

BGB002 Small molecule against an undisclosed novel target, implicated in EMT and acquired drug resistance. Lead-op stage.

MANAGEMENT Prof James Lorens, Chief Scientific OfficerDr David Micklem, Chief Technical OfficerDr Murray Yule PhD, Chief Medical Officer


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

Bioceros www.bioceros.com

CONTACTSBram Bout CEO

Nicole van de Vis-Box Assistant

ADDRESS Yalelaan 46 3584CM Utrecht The Netherlands

TELEPHONE +31 30 253 7910

FAX +31(0)84 730 9664


YEAR FOUNDED2003

FINANCIAL SUMMARY

Profitable by providing services in the area of generation and preclinical development of (therapeutic) monoclonal antibodies.

COMPANY PROFILE

Bioceros is a biotech company focusing on pre-clinical development of monoclonal antibodies. Bioceros has a hybrid business model: a) it offers services to the industry, which makes the company profitable and financially independent and 2) it generates and develops therapeutic monoclonal antibodies, primarily in the field of cancer and inflammation. Such therapeutics are developed either solely by Bioceros or in collaboration with partners. When proof of concept (pre-clinical) is obtained and robust IP is filed, the asset is spun out in a separate single asset legal entity. Two such realized spin-outs are BiocerOX B.V. (Bioceros affiliate) and Broteio Pharma B.V. (co-owned by Bioceros and Prothix B.V). Recently, BiocerOX granted exclusive worldwide rights to Janssen Pharmaceuticals, Inc. to develop its proprietary monoclonal antibody directed at an immune checkpoint regulator.

Broteio Pharma B.V. owns monoclonal antibodies directed at a complement factor for treatment of Antibody Mediated Diseases. This early asset is available for partnering. In addition, Bioceros is evaluating a number of interesting monoclonal antibody assets, which will become available for partnering when proof of concept is obtained.

MANAGEMENT Bram Bout, CEO and Chairman of the Management BoardRemco M. Brandt, Chief Operating Officer & Managing DirectorDr Louis Boon, Chief Scientific Officer


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

BioCrea www.biocrea.com

CONTACTTom Kronbach CEO

ADDRESS BioCrea GmbH Meissner Strasse 191 01445 Radebeul Germany

TELEPHONE +49 351 4043 0

Tom Kronbach +49 351 4043 3332

FAX +49 351 4043 3216


YEAR FOUNDED2010

FINANCIAL SUMMARY

Private Company, funded by project income

COMPANY PROFILE

BioCrea develops new small molecule drugs for debilitating CNS diseases such as Epilepsy, Autism, Dpression or Huntington’s disease.

The company’s team has an exceptional track record in the development of CNS drug candidates and has partnered extensively with major pharmaceutical companies such as Boehringer-Ingelheim, Pfizer, Wyeth and GlaxoSmithKline. biocrea is based in Radebeul, Germany.

MANAGEMENT

Tom Kronbach, Chief Executive OfficerDr Martin Gunthorpe, Chief Scientific Officer Prof Simon Ward, Executive Vice President Chemistry & DevelopmentDr Christiane Kronbach, Chief Operating Officer


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

BioLingus www.biolingus.ch

CONTACTSYves Decadt CEO

Didier Cocquoz CDO

ADDRESS Tüchelrosstrasse 9 CH-8248 Uhwiesen Switzerland

TELEPHONE +41 78 664 54 30


YEAR FOUNDED 2013

FINANCIAL SUMMARY

Funding stages : Seed : 1.9 MM CHF Round A : 7 MM CHF Round B : 19 MM CHF With this funding, we plan to enter with 5 products into development, over a 5 year period

COMPANY PROFILE

BioLingus is a privately owned biopharmaceutical company located in Switzerland. We are pioneering the development of oral (sublingual) administration of peptides and proteins (including vaccines and novel proteins scaffolds).

Our oral (sublingual) delivery technology unique characteristics, which we think gives us a competitive advantage versus many of our competitors.

MANAGEMENT

Yves Decadt, CEO Didier Coquoz, CDO Tom Ko, CTO


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

Biomay AG www.biomay.com

CONTACTRainer Henning, PhD CEO

ADDRESS Vienna Competence Center Lazarettgasse 19/1 A-1090 Vienna Austria

TELEPHONE +43-1-7966-296-100

FAX +43-7966-296-222


YEAR FOUNDED1984

FINANCIAL SUMMARY

Biomay is privately held with a share capital of EUR 17.6 million, exclusively provided by private investors.

COMPANY PROFILE

Biomay aspires to be a worldwide leader in research, discovery and development of disease modifying allergy therapeutics. Our products will dramatically improve the quality of life of patients by offering long-term cure for their disease.

We discover and develop recombinant allergy vaccines with a superior efficacy and safety profile. These innovative vaccines are based on cutting edge science for immunotherapy and prophylaxis that we generate in close cooperation with our academic partners. Our technology platform is based on a novel peptide carrier fusion protein approach and is broadly patent protected. Our lead product, the grass pollen allergy vaccine BM32, is currently in phase IIb clinical trials, with a recent positive interim analysis. In addition, we have candidate vaccines for house dust mite, cat dander, ragweed and birch pollen allergies in preclinical development.

The clinical efficacy of our products is demonstrated under the highest medical standards. We cooperate with leading allergy specialists and industrial partners to revolutionize allergy treatment solutions for the patients’ benefit.

Manufacturing of our own and our clients’ development products complies with the highest quality standards. Additionally, we support our clients by offering highly professional GMP contract manufacturing services.

MANAGEMENT

Rainer Henning, CEOKarl Fister, CFOHans Huber, COOAngela Neubauer, Head of Product Development


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

BMR Solutions Ltd www.bmrsolutions.co.il

CONTACTSRonen Kahana CEO

Dr Inessa Solomonik CTO

ADDRESS 49 Sokolov st, Herzeliya Israel

TELEPHONE 972-54-5696682 972-54-7349162

FAX 972-3-5432874


YEAR FOUNDEDSince March 2011

FINANCIAL SUMMARY

Privately held.

COMPANY PROFILE

BMR Solutions Ltd is a biopharmaceutical company engaged in development of innovative immunostimulant therapeutics and recovery of bone marrow after chemotherapy and/or radiation (e.g. after treatments for cancer or nuclear crisis). The company’s lead drug candidate BMRH-1001 and products pipeline demonstrate a novel scientific approach that combines the advantages of manufacturing and regulation path of “small molecule” drugs with the regenerative power of stem cells for treatments of immunodeficiency related sicknesses. Based on the proprietary discovery of the BMRH molecules that modulate early progenitor stem cells in the blood and bone marrow we achieve faster renewal of the blood and immune system which accelerates overall recovery and significantly increases survival rates and wellbeing.

MANAGEMENT

Ronen Kahana, CEODr Inessa Solomonik, CTOProf Azim Turdiev, CSOIgal Cohen, CFO


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

Bone Therapeutics SA www.bonetherapeutics.com

CONTACTWim Goemaere, MAE Chief Financial Officer

ADDRESS Bone Therapeutics 8 Rue Adrienne Bolland 6041 Gosselies BELGIUM

TELEPHONE +32 (0)2 529 59 90

FAX +32 (0)2 529 59 93


YEAR FOUNDED2006

FINANCIAL SUMMARY

To date Bone Therapeutics has raised e18 million in equity and €e14.8 million of non-dilutive public funding.

COMPANY PROFILE

Bone Therapeutics is a regenerative therapy company specializing in addressing unmet medical needs in the field of bone diseases and orthopaedics. The company is bringing a new and unique treatment paradigm in this field with novel differentiated bone-forming cells administered via a minimally invasive percutaneous approach, offering significant benefits over the current standard of care which involves heavy surgery and long recovery periods.

Today, Bone Therapeutics has 2 first-in-class products, addressing multiple indications, in clinical development. PREOB®, an autologous osteoblastic cell product is currently in phase III clinical trials for the treatment of osteonecrosis and non-union fractures, as well as in a phase I/IIa for severe osteoporosis; and ALLOB®, an allogeneic (“off-the-shelf”) osteoblastic cell product currently in a phase I/IIa for the treatment of delayed union.

With two pivotal “phase III” and two “phase II” trials ongoing, Bone Therapeutics can be considered as the most advanced regenerative company in its field. Moreover, ongoing pre-clinical programs, targeting other indications, and derived products should allow the company to further leverage its unique knowledge of the bone physiology and long-standing expertise in bone regeneration.

Bone Therapeutics’ regenerative products are manufactured to the highest GMP standards, comply with all regulations and are protected by a rich IP estate covering 11 patent families.

MANAGEMENT

Enrico Bastianelli, MD, MBA, Chief Executive OfficerWim Goemaere, MAE, Chief Financial OfficerValérie Gangji MD, PhD, Chief Scientific Officer


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

Calypso Biotech www.calypsobiotech.com

CONTACTAlain VICARI, DVM, PhD CEO

ADDRESS Chemin des Aulx, 14 Plan-les-Ouates CH-1228 Geneva Switzerland

TELEPHONE +41-22-552-3307

FAX +41-22-552-3309


YEAR FOUNDED2013

FINANCIAL SUMMARY

Early financing by MS-Ventures: 2.5 Mi EUR (2013).

COMPANY PROFILE

Calypso Biotech is a preclinical stage company discovering and developing antibody therapies for severe gastrointestinal diseases. Calypso Biotech pipeline includes one MMP-9 neutralizing antibody program for fistulizing Crohn’s disease, and an IL-15 neutralizing antibody program for refractory celiac disease. Both programs are planned to reach IND by end of 2015. Calypso Biotech mission is to bring those programs to early proof of concept in patients by 2017, considered as a favorable exit point. Calypso Biotech is looking for a 17 Mi EUR refinancing in 2014 to bring both programs to this exit point.

Calypso Biotech is a spin-off from Merck Serono and was created following the strategic decision by Merck-Serono to exit gastroenterology programs. Calypso Biotech current three employees are translational immunologists with a long rack-record in early drug development in the Pharma and Biotech industry. They previously designed and worked on the Merck Serono rheumatology and gastroenterology projects, one of them having been licensed in by Calypso Biotech.

Calypso Biotech offices and laboratory are located within the Eclosion incubator nearby Geneva, Switzerland

MANAGEMENT

Alain VICARI, DVM, PhD, CEOYolande CHVATCHKO, PhD, CSO


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

Canbex Therapeutics Ltd www.canbex.co.uk

CONTACTDr Jesse Schulman Chief Executive Officer

ADDRESS London BioScience Innovation 2 Royal College Street London NW1 0NH UK

TELEPHONE 0207 554 5872


YEAR FOUNDED2005

FINANCIAL SUMMARY

Series A ($3.2m) led by Merck Serono Ventures, closed in April 2013. Other investors include the Wellcome Trust, UCL Business, Fast Forward (US National Multiple Sclerosis Society), Esperante, Bloomsbury BioSeed Fund.

COMPANY PROFILE

Canbex is dedicated to improving the quality of life for people with multiple sclerosis (MS) and potentially other disorders, through better treatment for spasticity.

Spasticity is the sudden and uncontrollable movement of limbs and torso, and is among the most painful, damaging and debilitating symptoms of MS. Current drug treatments for spasticity are effective but are plagued by sedative and other side effects that sharply limit their usefulness.

Canbex closed a $3.2m financing round led by Merck Serono Ventures in April 2013, and its lead anti-spasticity compound, VSN16R, is set to enter Phase I safety testing. In studies to date, VSN16R shows substantially improved tolerability compared to other compounds, and is as effective against spasticity as any other agent known.

Supported by its leading London-based scientific and clinical team, Canbex believes that VSN16R has the potential to meet an important medical need, and to address a highly attractive commercial opportunity.

MANAGEMENT

Operational ManagementDr Jesse Schulman, Chief Executive OfficerDr Keith Powell, ChairmanDr Miroslav Ravic, Chief Medical Officer

Scientific and ClinicalProf David Selwood, Chief Scientific OfficerProf David Baker, Head of BiologyProf Gavin Giovannoni, Chief Clinical Advisor


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

Cardio3 BioSciences www.c3bs.com

CONTACTSDr Christian Homsy CEO

Anne Portzenheim Communication Manager

ADDRESS Rue Edouard Belin 12 1435 Mont-Saint-Guibert Belgium

TELEPHONE +32 10 39 41 00


YEAR FOUNDED 2007

FINANCIAL SUMMARY

Cardio3 BioSciences’ shares are listed on NYSE Euronext Brussels and NYSE Euronext Paris under the ticker symbol CARD.

COMPANY PROFILE

Cardio3 BioSciences is a leading biotechnology company focused on the discovery and development of regenerative and protective therapies for the treatment of cardiac diseases.

Cardio3 BioSciences leverages research collaborations in the US and in Europe with Mayo Clinic and the Cardiovascular Centre Aalst, Belgium.

The Company’s most advanced therapy, C-Cure®, is a highly innovative stem cell approach for the treatment of heart failure, one of the world’s most pressing unmet medical needs.

Based on a comprehensive strategy developed by Cardio3 BioSciences and leveraging technology licensed from Mayo Clinic, the C-Cure®programme is designed to direct the patient’s own stem cells into new heart cells with the potential to repair damaged tissue and improve heart function, clinical outcomes and quality of life.

Having achieved positive Phase II results, C-Cure® is currently being tested in Europe in a Phase III trial (CHART-1 – Congestive Heart failure Cardiopoietic Regenerative Therapy). CHART-1 is the world’s first phase III trial using pre-programmed cardiac progenitor cells for the treatment of heart failure.

Cardio3 BioSciences has also received the authorization from the U.S. FDA for clinical testing of the Company’s proprietary regenerative medicine product C3BS-CQR-1 (C-Cure®) as a treatment

The Cardio3 BioSciences team has extensive experience in developing and commercialising new pharmaceutical products and medical technologies and the Company’s current strategy is to drive the clinical development of C-Cure® and to market the product itself, if marketing authorisation is obtained, on a wide geographical scale.

Cardio3 BioSciences has also developed C-Cath®ez, the most technologically advanced injection catheter with superior efficiency of delivery of bio therapeutic agents into the myocardium.

Cardio3 BioSciences was founded in July 2007 and is based in Mont-Saint-Guibert in the Walloon region of Belgium.

MANAGEMENT

Dr Christian Homsy, CEO


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

Crescendo Biologics www.crescendobiologics.com

CONTACTMike Romanos CEO

ADDRESS Crescendo Biologics Ltd Meditrina Building Babraham Research Campus Cambridge CB22 3AT

TELEPHONE +44 (0) 1223 497140

FAX +44 (0) 1223 497141


YEAR FOUNDED 2009

COMPANY PROFILE

Crescendo Biologics, based in Cambridge, UK, is focused on the discovery and development of best-in-class human VH antibody fragment therapeutics using its novel transgenic platform. Crescendo is enabling the major VH product formats (multivalent, half-life-extended and topical) for its own pipeline, focused in inflammation and oncology, and to make it the partner of choice for human VH fragment therapeutics.

MANAGEMENT

Mike Romanos, PhD, CEO Matthew Roe, Business Development Clive Dix, Chairman


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

[email protected]

ADDRESS Ceronco Biosciences, PO Box 85696, 2508 CJ Den Haag, The Netherlands


FINANCIAL SUMMARY Ceronco is seeking its first round of investment and partnerships for selected development candidates.

COMPANY PROFILE

Ceronco Biosciences is a preclinical stage company developing a novel technology to enhance treatment of cancer and limit or overcome drug resistance.

Our nanotechnology targets the tumor cell membrane as a novel target in cancer treatment. The short-chain lipids modulate the tumor cell membrane, enhancing efficacy and safety of known chemotherapeutic drugs and molecular targeted drugs (kinase inhibitors).

Proof-of-concept of this technology has been obtained with GC-nanoliposomes loaded with doxorubicin, CB001, which is ready for clinical phase in 2014.

Several other development candidates built on this platform have been identified to fuel our pipeline.

Ceronco Biosciences www.ceronco.nl


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

F4 Pharma GmbH i.G. www.f4-pharma.com

CONTACTDr Petra Wülfroth COO

ADDRESS Bürgerspitalgasse 24/10 1060 Vienna

TELEPHONE +41 55 534 7882

FAX +41 55 534 4682

EMAIL petra.wuelfroth @accella-advisors.com

YEAR FOUNDED2014

COMPANY PROFILE

F4 Pharma is a development stage company who is concentrating on diseases associated with vascular leakage and reperfusion injury. Reperfusion injury as it is seen after transplantation will be the first target indication. Vascular leakage - a detrimental clinical situation occuring after shock situations of different etiology - will be the basis for follow- up indications. A complete ph I data package and ph IIa safety results from another indication, allow a direct ph II start. The focus will be on rare or even ultra- rare diseases leading to orphan designation.

MANAGEMENT

Mag. Thomas Steiner, CEODr Petra Wülfroth, COO


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

Forendo Pharma Ltd www.forendo.com

CONTACTRisto Lammintausta CEO

ADDRESS Itäinen Pitkäkatu 4B FI-20520 Turku Finland

TELEPHONE +358 40 310 8010


YEAR FOUNDED2013

FINANCIAL SUMMARY

In June 2013 company has raised the seed funding of 3.5 M€ from Novo Seeds, Karolinska Development and Finnvera and R&D loan of 1.5 M€ from Tekes. Working for the next financing round.

COMPANY PROFILE

Forendo Pharma is a new drug discovery and development company. The core team has long experience in development of hormonal drugs, latest ospemifene, launched in USA in 2013.

The main focus is today to bring the novel HSD17B1 inhibitor concept to clinical POC in endometriosis.

HSD17B1 enzyme is a new target to leverage estrogen effect in specific target organs, like endometriosis lesions.

The new compounds have demonstrated efficacy in primate disease model without effect on circulating hormones.

Fispemifene has demonstrated POC in phase II in normalizing low testosterone production in men with secondary hypogonadism. This SERM offers advantages over the existing therapies by activating own testicular function with once daily oral dosing. Forendo is looking for partners to bring that product to the market.

MANAGEMENT

Board of Directors:Stephan Christgau, Chairman (Novo Seeds)Tomas Odergren, (Karolinska Development)Jyrki Mattila, (BioDeal Partners, USA)Risto Lammintausta, CEO


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

F-star www.f-star.com

CONTACTJohn Haurum CEO

ADDRESS Moneta B280 Babraham Research Campus Cambridge, CB22 3AT UK

TELEPHONE +44-7739-174297

FAX +44-1223 497461


YEAR FOUNDEDF-star GmbH (2006)F-star Alpha Ltd (2013)

FINANCIAL SUMMARY

F-star GmbH €29M F-star Alpha Ltd €9.4M

COMPANY PROFILE

F-star is a biopharmaceutical company with a focus on immune-oncology dedicated to developing novel bispecific antibody products that provide a significant improvement over the current standard of care. Given its strong patent position, it is the only biopharmaceutical company with the ability to create and develop Fcab™ antibody fragments, and bispecific antibodies, by modifying the constant region of an antibody. In particular, F-star’s Modular Antibody Technology™ enables rapid discovery and development of bispecific antibodies by introducing additional binding sites to the constant region of an antibody and offers unprecedented ease in the development and manufacturing of bispecific monoclonal antibodies. Using the Modular Antibody Technology™, F-star generates bispecific antibodies (mAb2™) that possess the favourable characteristics of traditional monoclonal antibodies, without the production challenges often associated with other antibody formats. F-star is now applying its proprietary technology to the development of a pipeline of product candidates.

In October 2013 an asset-centric vehicle (“F-star Alpha Ltd.”) was established to create greater commercial and financial flexibility for F-star, the investors, and future partners. F-star was selected by the industry newsletter FierceBiotech as one of the Fierce 15 winners in 2011, designating it as one of the most promising private biotechnology companies in the industry. F-star currently employs over 30 people at its research site in Cambridge, UK.

MANAGEMENT

John Haurum, CEOTolga Hassan, CFOJane Dancer, CBOHaijun Sun, VP Biological ProductsMihriban Tuna, VP DiscoveryKate Seaber, Executive Programme DirectorJohn Edwards, Chairman of the Supervisory Board


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

Grünenthal GmbH www.grunenthal.com

ADDRESS Grünenthal GmbH 52099 Aachen

TELEPHONE +49 241 569-0


COMPANY PROFILE

The Grünenthal Group is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany. Building on its unique position in pain treatment, its objective is to become the most patient-centric company and thus to be a leader in therapy innovation.

Grünenthal is one of the last five remaining research-oriented pharmaceutical companies with headquarters in Germany which sustainably invests in research and development. Research and development costs amounted to about 26 percent of revenues in 2012. Grünenthal’s research and development strategy concentrates on selected fields of therapy and state-of-the-art technologies. We are intensely focused on discovering new ways to treat pain better and more effectively, with fewer side-effects than current therapies.

Altogether, the Grünenthal Group has affiliates in 26 countries worldwide. Grünenthal products are sold in more than 155 countries. Today, approx. 4,400 employees are working for the Grünenthal Group worldwide. In 2012, Grünenthal achieved revenues of €973 mn.

More information: www.grunenthal.com


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

Imanova www.imanova.co.uk

CONTACTSDr Kevin Cox CEO

Miss Emaily Head

Miss Mirca Scagliosi

ADDRESS Imanova Ltd Burlington Danes Building Imperial College London Hammersmith Hospital London, W12 0NN

TELEPHONE +44 (0) 20 8008 0625

FAX +44 (0) 20 8008 6491


YEAR FOUNDEDFeb 2011

COMPANY PROFILE

Imanova Ltd is a London-based center of excellence in imaging sciences. It is an innovative alliance between the UK’s Medical Research Council and three world-class London universities: UCL, King’s College London and Imperial College London.

Imanova and its partners bring together a breadth and depth of knowledge and expertise that will drive research and innovation in imaging sciences. The company owns and manages the former GSK Clinical Imaging Centre located at Imperial College London’s Hammersmith Hospital campus.

We provide world class translational medicine capabilities by bringing together state-of-the art scanning equipment, radio-ligand development and manufacture and imaging research methodology.

MANAGEMENT

Dr Kevin Cox. CEOProf Roger Gunn, Chief Scientific Officer and Head of AnalysisDr Jan Passchier, Director of Operations and Head of Radiochemical SciencesDr Ilan Rabiner, Director of Clinical Cpplications


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

ImmunID www.immunid.com

CONTACTSBernhard Sixt, PhD Chairman and CEO

ADDRESS ImmunID 7, parvis Louis Néel BP50 38040 Grenoble France

TELEPHONE +33 (0) 438 785 770

FAX +33 (0) 438 785 837


YEAR FOUNDED2005

FINANCIAL SUMMARY

$5m investments, several $ millions in grants.

COMPANY PROFILE

ImmunID is a pioneer of immune molecular diagnostics aiming to set the global immune diagnostics standard. Its clinical product ImmunTraCkeR evaluates the T cell repertoire diversity at the genomic level. The company is ISO9001/ISO13485 accredited and provides testing worldwide to leading clinical centers and blue-chip pharmaceutical companies.

ImmunTraCkeR and ImmunIg are proprietary immune molecular diagnostics test analysing and quantifying immune competence. ImmunTraCkeR measures T-Cell repertoire diversity and ImmunIg measures B-Cell repertoire diversity using multi-N-plex qPCR on genomic DNA.

Current industrial customers are Roche, Sanofi-Pasteur, and confidential cooperations. Current clinical research customers in Europe, US and Asia.

MANAGEMENT

Bernhard Sixt, PhD, Chairman and CEOKurt Schmidt, Chief Financial Officer


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

Immunovaccine Inc. www.imvaccine.com

CONTACTSDr Marc Mansour Chief Operating Officer & Director

Albert Scardino Executive Chairman

ADDRESS 1344 Summer Street, Suite 412 Halifax, Nova Scotia B3H 0A8 CANADA

TELEPHONE 902-492-1819

FAX 902-492-0888


YEAR FOUNDED2000

FINANCIAL SUMMARY

Shares outstanding: 79.1M Recent Market Cap: $91.7M Recent share price: $1.16 52 Week Range: $0.22 - $1.50 Average Daily Volume: 108,000 Cash & Other Cash Resources (30/09/13): $1.14M

COMPANY PROFILE

Immunovaccine is a biotechnology company focused on the application of its novel vaccine delivery platform to the development of vaccines for cancer therapy and infectious diseases. The Company’s DepoVax™ platform is a patented lipid delivery system that presents antigens plus adjuvant to the immune system for a prolonged period and has the potential to enhance immune responses. Immunovaccine has advanced its platform technology and proprietary cancer vaccine into Phase I clinical trials and has demonstrated both safety and immunogenicity potential. We are planning two randomized Phase II clinical trials combining our lead clinical candidate, DPX-Survivac, with an immune modulator in ovarian cancer and glioblastoma. Immunovaccine is also capitalizing on the broad potential of its delivery platform by creating new DepoVax-based vaccines through multiple development collaborations. In addition to the Company’s human health vaccine strategy, it continues to capture value from licensing opportunities. Immunovaccine has several key partnerships in the animal health sector including an agreement with Zoetis, which has licensed the Company’s delivery technology platform to develop vaccines for livestock.

MANAGEMENT

Kimberly Stephens, CFOMarc Mansour, Ph.D., COO & Director

Board of Directors:Albert Scardino, Executive Chairman, Communications Strategist, Pulitzer Prize RecipientWade Dawe, CEO of Brigus GoldDr Llew Keltner, Former CEO of AgonOxJames Hall, CA, Sr. VP of Investments, GrowthWorksStephanie Léouzon, Senior Advisor to Torreya PartnersDr Marc Mansour, Ph.D., COOWayne Pisano, Former President and CEO of Sanofi PasteurBrad Thompson, CEO of Oncolytics


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

IntegraGen www.integragen.com

CONTACTSMr Bernard Courtieu CEO

Mrs Laurence Riot Lamotte CFO

ADDRESS 5 rue Henri Desbruères Genopole Campus 1 F-91000 - EVRY FRANCE

TELEPHONE +33. 160 910 900

FAX +33 .160 777 910


YEAR FOUNDED2000

FINANCIAL SUMMARY

Financials in Ke 2013 2012 2011

Revenues 5,440 4,741 4,649 Operating Expenses n/a 7,173 7,241 EBIT n/a -2,368 -2,402 Net Result n/a -1,726 -2,040

Cash 4,875 4,649

COMPANY PROFILE

IntegraGen (ALINT.PA) is a biotechnology company focused on the development and commercialization of molecular diagnostic tests in the fields of autism and oncology. IntegraGen’s mission is to translate molecular research into clinical practice through the identification of novel genetic biomarkers and the subsequent development of molecular diagnostic tests which allow clinicians to better manage the clinical care of their patients. IntegraGen is also a leader in delivering expert genomic service solutions to academic researchers and life sciences companies as a result of its scientific knowledge and technological expertise related to cutting edge genomic platforms and bioinformatics.

The company is listed on Alternext (NYSE Euronext Paris).

MANAGEMENT

Bernard Courtieu, CEOLaurence Riot Lamotte, CFOFrançois Liebaert, VP Director of R&D and Regulatory affairsLarry Yost, General Manager, INTEGRAGEN INC Francis Rousseau, Director of GenomicsEmmanuel Martin, Director of Marketing and Business Development


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

Interceptin

CONTACTSMichele Marzola CEO

Marco Colombatti CSO

ADDRESS Stradone San Fermo 14 37121 Verona - Italy

TELEPHONE +39-045-592993

Michele Marzola +39-334-3473285

Marco Colombatti +39-349-1933836

FAX +39-045-592993


YEAR FOUNDED2011

FINANCIAL SUMMARY

Investments required: e7 M to complete Phase II for diagnostic solution e18 M to complete Phase II for therapeutic solution

Expected exit > e1 BN by 2019

COMPANY PROFILE

Interceptin proposes the most advanced diagnostic and therapeutic treatment for prostate cancer and all other tumors expressing PSMA (stomach, colon). Our solution is based on a recombinant single chain antibody fragment, which associated with a radioisotope I-123 maps perfectly all forms of prostate tumor, including the smallest metastases. When associated with a non-immunogetic toxin, Interceptin is a powerful ADC capable of reducing tumor masses to almost nil with just a few injections, leading to a complete healing without invasive or debilitating traditional treatments. Furthermore, our antibody fragment carries multiple payloads, hence toxins can be combined with I-131 or advanced chemio for a more effective and complete treatment. The theranostic features of Interceptin permit to tailor frequency and intensity of injections to the characteristic of each patient, arriving at fully tailored therapies. Our pharmacoeconomics are very favourable, with a 5x lower cost per patient than current Gold Standard with much better clinical impact. We will address a $ 8 BN market with > 600 k patient p.a. for prostate cancer and > 600 K patient for gastro and colorectal cancer. We expect to be able to generate more than > 2 BN revenues for our future acquiror.

MANAGEMENT

Michele Marzola, Chief Executive OfficerInvestor with experience in more than 20 start-ups. Previously GM IBM in Europe and Principal Booz, Allen & Hamilton. MBA

Columbia University and MS Enginnering Bologna

Marco Colombatti, Chief Scientific Officer Professor Immunology, University of Verona (Italy), MD. PhD in Oncology, University of Padua. Worked in Lausanne and

Bethesda (MD).

Partnership with Istituto Nazionale Tumori – Milan; primary Advisory Board


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

InteRNA Technologies www.interna-technologies.com

CONTACTRoel Q.J. Schaapveld, PhD, MBA CEO

ADDRESS Hugo R. Kruyt building Padualaan 8 3584 CH Utrecht The Netherlands

TELEPHONE +31 30 253 2386

FAX +31 30 253 9176

EMAIL schaapveld @interna-technologies.com

YEAR FOUNDEDDecember 2006

FINANCIAL SUMMARY

Series A

Investors: • Aglaia Oncology Fund • PPM Oost • Informa investors • CEO

COMPANY PROFILE

InteRNA Technologies is a Dutch pre-clinical stage drug discovery and development company with the mission to develop miRNA-based pathway targeted therapeutics for cancer.

InteRNA focuses on miRNAs that control genes connected in signal transduction pathways and biological processes that are known to play a role in cancer initiation, progression and metastasis, and in resistance to current treatments.

InteRNA has exclusive access to the largest miRNA library of any company and has developed a promising platform for discovery and validation of miRNA-based drug candidates against previously undruggable targets in cancer and other major diseases (e.g. eye and neurodegenerative).

InteRNA’s miRNA target identification and validation platform has delivered multiple novel drug candidates for which the downstream biology and biomarkers have been elucidated. With the in vivo Proof of Concept (PoC) of intravenously administered formulated, chemically modified miRNA mimics in glioblastoma and melanoma tumor models, the validated platform has shown to select bona fide drug candidates from the functional screens in cell-based assays.

InteRNA’s lead compound, a mimic of miRNA-3157, shows great promise to qualify for treatment of melanoma patients that are intrinsic resistant to or became resistant upon treatment with the B-Raf kinase inhibitor Zelboraf® (vemurafenib).

MANAGEMENT

Roel Q.J. Schaapveld, PhD, MBA, CEO


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

Inthera Bioscience AG www.intherabio.com

CONTACTDr Ulrich Kessler CEO/CSO

ADDRESS Inthera Bioscience AG Ruetistrasse 14 CH-8952 Schlieren Switzerland

TELEPHONE +41-44-2002112

FAX +41-44-200


YEAR FOUNDED2013

COMPANY PROFILE

Inthera Bioscience is developing protein domain mimetics (PDMs) as inhibitors of intracellular protein-protein interactions (PPIs) employing its proprietary Hydrogen Bond Surrogate (HBS) technology. HBS-constrained peptides merge the versatility of small-molecules with the specificity of biologics, a unique combination that is utilized to tackle untapped targets in a multitude of disease states. The broad applicability of the technology platform has been illustrated against several targets in oncology and virology.

Initial in vivo data on Inthera’s lead compounds targeting hypoxia-induced signaling and Ras- activation indicate their potential to break new ground in the treatment of cancer types with poor prognosis such as triple negative breast and pancreatic cancer. HBS-constrained peptides easily penetrate cells, are well tolerated, exhibit very good pharmacokinetic properties and the manufacturing process is straightforward.

MANAGEMENT

Dr Ulrich Kessler, CEO/CSOProf Paramjit Arora, CTOChristophe Berger, COORoland Walder, CFO

INTHERA!Bioscience!


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

Isarna Therapeutics www.isarna-therapeutics.com

[email protected] ADDRESS Isarna Therapeutics GmbH, Leopoldstr. 254-256, 80807 München

TELEPHONE +49/89/890-831-0

FAX +49/89/890-831-491


YEAR FOUNDED 1998

FINANCIAL SUMMARY

The company’s investors include MIG Fonds, S-Refit, AT NewTec, and Bayern Kapital.

COMPANY PROFILE

Isarna Therapeutics GmbH has an unmatched commitment to developing TGF-beta inhibitors that stimulate the human immune system to effectively fight cancer. We are advancing a unique pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcome.

MANAGEMENT

Philippe P. Calais, Ph.D., CEOMichel Janicot, Ph.D., CSOEugen Leo, M.D., Ph.D., M.B.A., CMO


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

Lead Discovery Center GmbH www.lead-discovery.de

CONTACTThomas Hegendoerfer Head of Business Development

ADDRESS Otto-Hahn-Str. 15 44227 Dortmund Germany

TELEPHONE +49-231-9742-7000

FAX +49-231-9742-7039


YEAR FOUNDED 2008

COMPANY PROFILE

Paving the way for innovative medicines.

The Lead Discovery Center (LDC) was established in 2008 by Max Planck Innovation as a novel approach to capitalize on the potential of excellent basic research for the discovery of new therapies for diseases with high medical need.

Our aim is to translate promising early-stage projects into innovative pharmaceutical lead compounds with PoC in animal.

With a world-class, interdisciplinary team of scientists, drug discovery experts, pharmacologists and seasoned project managers, the LDC offers the full scope of drug discovery services – from target to lead – according to the highest industry standards. As an independent company with an entrepreneurial outlook, we engage with research institutions, universities and industry in collaborative drug discovery efforts.

Focusing on small molecules, the LDC conducts drug discovery projects originating primarily from academic groups and sustains a preferred partnership with the Max Planck Society. Projects are developed in close collaboration with the project owner.

LDC sustains industry partnerships with AstraZeneca, Bayer and Merck Serono and is a founding member of the Global Alliance of Leading Drug Discovery & Development Centres.

MANAGEMENT

Managing DirectorsBert Klebl, PhD, Managing Director and Chief Scientific OfficerPeter Nussbaumer, PhD, Managing Director and Head of Medicinal Chemistry

Department HeadsMatthias Baumann, PhD, Head of PharmacologyAxel Choidas, PhD, Head of BiologyJan Eickhoff, PhD, Head of Assay Development & ScreeningMichael Hamacher, PhD, Head of Administration & FinanceThomas Hegendörfer, Head of Business Development


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

MDxHealth (MDXH) www.mdxhealth.com

CONTACTSDr Jan Groen Chief Executive Officer

Francis Ota EVP Finance

ADDRESS CAP Business Center Rue d’Abhooz, 31 4040 Herstal BELGIUM

15279 Alton Parkway, Suite 100 Irvine CA, 92618 USA

TELEPHONE BE : +32/4.364.20.70 US : +1.949.812.6979

FAX BE : +32/4.364.20.71 US : +1.949.242.2960


YEAR FOUNDED2003

FINANCIAL SUMMARY

September 2013 in ‘000 EURCommercial revenues : 4,525EBIT : - 8,951Cash in hand : 21.054Financial debt : 0Q2 – Company raised 18 million EUR

COMPANY PROFILE

MDxHealth is a molecular diagnostics company that develops and commercializes advanced epigenetic tests for cancer assessment and the personalized treatment of patients. The company’s first commercial product, ConfirmMDxTM for Prostate Cancer, has been shown to help distinguish patients who have a true-negative biopsy from those who may have undetected cancer. MDxHealth helps to address a large and growing unmet medical need for better cancer diagnosis and treatment information. The company has a proprietary platform and a strong epigenetic product pipeline focused on the development of products for prostate, brain and lung cancers. The company is based in Irvine, California with a European headquarters in Herstal, Belgium. For more information visit MDxHealth’s website at www.mdxhealth.com and follow us on Twitter at: twitter.com/mdxhealth.

MANAGEMENT

Dr Jan Groen, CEOChristopher Thibodeau, EVP Commercial OperationsJoe Sollee, EVP Corporate Development & Legal AffairsFrancis Ota, EVP Finance


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

Medicyte GmbH www.medicyte.com

CONTACTBirgit Tramnitz, Ph.D. Business Development

ADDRESS Medicyte GmbH Im Neuenheimer Feld 581 69120 Heidelberg Germany

TELEPHONE +49-6221-7292530

FAX +49-6221-7292530


YEAR FOUNDED2007

FINANCIAL SUMMARY

Medicyte is privately funded.

COMPANY PROFILE

Medicyte is specialized in the controlled, scalable propagation and standardization of human primary cells and provides ground-breaking unique research & development products to the pharmaceutical, chemical and cosmetics industries and to academic institutions.

The product portfolio comprises primary cells like hepatocytes and cardiomycytes retaining their native characteristics for R&D at virtually unlimited access, but of exceptional consistent quality and absolute reproducibility as well as cultivation media, kits and accessories.

Based on Medicyte’s proprietary cell proliferation platforms for drug development the company has also become engaged in the development of cell-based therapies.

MANAGEMENT

Björn F. Lindemann, Ph.D., CEOJoris Braspenning, Ph.D., CSO


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

MedLumics S.L. www.medlumics.com

CONTACTEduardo Margallo [email protected] +34 610 01 27 48

ADDRESS Medlumics S.L. Ronda de Poniente 16 – 1E 28760 Tres Cantos SPAIN

TELEPHONE +34 91 803 39 25

Eduardo Margallo +34 610 01 27 48

FAX Fax: +34 91 804 93 21


YEAR FOUNDED2011

FINANCIAL SUMMARY

MedLumics is currently seeking a B-Round of €12M to support its expansion from 2014Q3. These funds take the company to break-even in 2017 and are applied to two main indication areas: The commercial out-license in 2014H2 of a dermatology imaging product providing high resolution information of the skin to support first-line diagnostics and therapy guidance, and the development, clinical validation and commercial launch of an RF Ablation catheter Medlumics reaches break-even in 2017 with fast-growing revenues in the last two years of operations. The product license in dermatology shall validates the platform but also support the launch of the guided RF ablation line, minimizing capital needs and improving scalability into a high upside market.

COMPANY PROFILE

MedLumics is a diagnostic imaging company developing a new generation of portable clinical systems that generate high resolution images of tissue. These devices are based on optical coherence tomography (OCT), an established imaging modality in ophthalmology with fast growing applications in other fields of medicine. The company has developed an optical chip that allows a radical reduction in system size and complexity while offering unprecedented image features. Its unique technology also supports novel catheter designs.

MedLumics’ is finishing the development of a first-in-class hand-held device to support the management of skin tumors using OCT information. This opportunity represents a market of 180M$/yr. The product is expected to launch in the second half of 2014, providing high-quality OCT at a price compatible with broad adoption. By incorporating standard epiluminescence microscopy, it allows for seamless integration with current clinical workflows.

In parallel, MedLumics is developing an OCT-guided RF ablation catheter for use in atrial fibrillation management. With an opportunity exceeding 1.3B$/yr., the target launch date for this product is 2015H2. MedLumics’ unique catheter design shall provide accurate monitoring of energy delivery to tissue and direct visualization of lesion size and continuity, thus reducing recurrence rates and procedure time.

MANAGEMENT

Eduardo Margallo, PhD, President & CEOPioneer in the photonic integration of optical coherence tomography (8+ yr. experience) and with a strong background in business administration and management.

Jose Luis Rubio, PhD, VP & CTOExpert in medical imaging (8+ yr. experience) with a deep understanding of the challenges and potential of integrated optics for optical coherence tomography, and an specialization in IP and innovation management.

Miguel Eslava, VP & COOEx-general manager at GE Healthcare for Spain and Portugal, with a strong international business network and a solid experience (over 30yr.) in operations, quality management and team leadership.

Pedro Oliveira, Marketing ManagerOver 10yr international experience in Business Development and Product Management at J&J.

Lucía Colmenero, Finance ManagerSolid experience in financial management of technology start-ups.


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

Metys Pharmaceuticals www.metys-pharma.ch

CONTACTSMichael Scherz Founder & Chief Executive Officer

Patrick Scherrer Lead Financial Advisor

ADDRESS Steinenring 8, CH-4051 Basel

TELEPHONE Michael Scherz +41 79 408 79 82

Patrick Scherrer +41 79 200 98 31


YEAR FOUNDED2013

FINANCIAL SUMMARY

CHF 100’000.- as 100’000 name shares at CHF 1.00 per share. Seed investment round in Nov 2013, CHF 740’000

Investment ObjectivesSeries A investment round, up to CHF 18’000’000

COMPANY PROFILE

Metys Pharmaceuticals signed an Option Agreement on 10 June 2013 with Neurotune AG, Schlieren, ZH, Switzerland, giving Metys exclusive world-wide option for all indications to dimiracetam and related compounds.

Dimiracetam is a small molecular weight drug of the racetam class, in clinical development for the treatment of neuropathic pain. In animal models the compound has an efficacy profile superior to pregabalin (Lyrica™) and other prominent anti-neuropathic agents. Dimiracetam has completed healthy subject testing as well as a safety- & tolerability-study in HIV patients.

Metys is preparing the first dedicated efficacy study of dimiracetam in HIV-associated painful neuropathy. Dimiracetam is protected by method-of-use patents granted in major markets, and other patent applications granted or pending.

Metys is also entered a successor compound into preclinical development for the treatment of neuropathic pain, including neuropathic pain of osteoarthritis.

MANAGEMENT

Michael Scherz, CEO & Founderformerly Vice President, Life Cycle Management, Actelion Pharmaceuticals

Patrick Scherrer, Lead Financial Advisorformerly CEO, Widmann Associates


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

MiNA Therapeuticswww.minatx.com

CONTACTRobert Habib CEO

ADDRESS 1 Vincent Square London SW1P 2PN United Kingdom

TELEPHONE +1 917 455 3503

FAX +44 203 514 2252


YEAR FOUNDED2008

COMPANY PROFILE

MiNA Therapeutics is pioneering activation of gene expression with short activating RNA (saRNA)

Harnessing a proprietary algorithm, MiNA is developing a revolutionary class of therapeutics that activate key genes in major disease pathways. MiNA’s ability to selectively activate master regulatory genes represents a new frontier in precision medicine.

MANAGEMENT

Nagy Habib, ChairmanPeter Bains, Non Executive DirectorChris Wood, Non Executive DirectorRobert Habib, CEO


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

MolMed S.p.A. www.molmed.com

CONTACTPaolo Bassanini Business & IR

ADDRESS Via Olgettina 58, 20132 Milan, Italy

TELEPHONE +39 221 277205

FAX +39 221 277220


YEAR FOUNDED 1996

FINANCIAL SUMMARY

2008 IPO 2010 capital increase 2013 capital increase

COMPANY PROFILE

MolMed S.p.A. is a biotechnology company focused on research,development and clinical validation of novel anticancer therapies.

MolMed’s pipeline includes two novel anticancer therapeutics in clinical development: TK, a cell-based therapy enabling bone marrow transplants from partially compatible donors, in Phase III for high-risk leukaemia, and NGR-hTNF, a novel vascular targeting agent, in Phase III for malignant pleural mesothelioma and in Phase II for six other different types of solid tumours (colorectal, smallcell lung, non-small-cell lung, liver and ovarian cancers, and soft tissue sarcomas).

MolMed is headquartered at the San Raffaele Biomedical Science Park in Milan, Italy.

MolMed is listed on the main market (MTA) of the Milan Stock Exchange, managed by BORSA ITALIANA.

MANAGEMENT

Claudio Bordignon, Chairman & CEOMarina Del Bue, General Manager Business AdministrationGermano Carganico, General Manager R&D and Operation


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

Neurimmune Holding AG www.neurimmune.com

CONTACTSMichael Salzmann COO & General Manager

ADDRESS Wagistrasse 13 CH-8952 Schlieren Switzerland

TELEPHONE +41 44 755 46 46

FAX +41 44 755 46 47


YEAR FOUNDED2007

FINANCIAL SUMMARY

USD 100+ million revenues to date through down-payments and milestones, long sustainable runway. Aggregate Deal Volume: USD 832.5 million.

COMPANY PROFILE

Neurimmune is a biopharmaceutical company dedicated to the development of immunotherapeutics for the treatment and prevention of human disorders with a focus on protein aggregation diseases. Based on its unique RTM™ technology platform (Reverse Translational Medicine), Neurimmune pursues a novel and revolutionary approach for the development of proprietary human monoclonal antibodies as therapeutics with unique advantages that result in superior risk profiles and excellent efficacy.

Neurimmune develops human antibodies as drug candidates for CNS and other indications, with a lead program for Alzheimer’s disease in Phase 1 clinical trials. Further therapeutic RTM™ derived antibodies are under development in strategic partnerships for Alzheimer’s disease, Parkinson’s disease and ALS.

MANAGEMENT

Michael Salzmann, PhD, COO & General ManagerJan Grimm, PhD, CSODirk Schimkat, CFO


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

NeurolifeScienceswww.neurolifesciences.com

CONTACTChris Zwyer CEO

ADDRESS NeuroLifeSciences SAS 1, Rue de Stockholm 75008 Paris France

TELEPHONE +33 1 44 70 72 02

FAX +33 1 44 70 00 19


YEAR FOUNDED2013

COMPANY PROFILE

NeuroLifesSciences is focusing on the repurposing of safe and (cost-)effective compounds to treat a variety of developmental disorders affecting behavior and cognition, especially ADHD.

BLK-021 is the company’s most advanced compound. Its active ingredient is Mazindol, a wake-promoting agent and a non-amphetamine stimulant developed by Sandoz-Wander and approved by the FDA in 1973 for pediatric obesity. Mazindol has an outstanding, long-term safety profile and is therefore addressing game-changing, unmet market needs in CNS/ADHD.

NeuroLifesSciences is seeking strategic partners to develop and/or to market BLK-021 – a new approach which will redefine the ADHD therapy of the future.

MANAGEMENT

Chris Zwyer, CEO & Co-FounderEric-Jean Desbois, CFO & Co-FounderEric Konofal, CMO & Co-FounderBruno Figadère, CSO & Co-Founder


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

Numab www.numab.com

CONTACTOliver Middendorp CBO & Co-CEO

ADDRESS Numab AG Einsiedlerstrasse 34 CH-8820 Wädenswil Switzerland

TELEPHONE +41 44 533 0471

FAX +41 44 533 0470


YEAR FOUNDED 2011

FINANCIAL SUMMARY

The Company is financed through its collaboration revenues.

COMPANY PROFILE

Numab is a privately owned Swiss biotech company focusing on the discovery and development of antibody fragment-based therapeutics. The 13 people Company being operational since January 2012 has signed two revenue-generating industry collaborations and is currently moving its first proprietary bi-specific lead molecule into preclinical development.

Numab’s lead product (ND003) is being developed for the treatment of severe asthma. ND003 eliminates the disease-driving eosinophil cells, a concept that has been successfully validated in the clinic by benralizumab. The main differentiator to benralizumab is that ND003 shall be applied by inhalation, thereby aiming for a faster onset of therapeutic effect – a difference that can potentially be life-saving. Numab’s second proprietary product (ND007) has been designed to treat severe chronic inflammatory diseases and cancer. Both, ND003 and ND007 exploit Numab’s proprietary best-in-class anti-CD3 T cell engager to eliminate pathogenic cells.

Numab is led by a Management with proven track record in the biotech industry (4 out of 5 Management members have been long lasting employees in key positions at ESBATech).

Numab applies proprietary breakthrough technology that allows for fast and reproducible discovery of best-in-class antibody fragment based therapeutics.

The technology is used to broaden Numab’s proprietary pipeline and for discovery partnerships with the pharmaceutical industry.

The Company is currently raising money to expedite its lead program into the clinic.

MANAGEMENT

David Urech, PhD, CSO & Co-CEOOliver Middendorp, PhD, CBO & Co-CEOTea Gunde, PhD, Head of PharmacologySebastian Meyer, PhD, Head of BiochemistryRoland Helfenstein, Head of Finance and Administration


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

OCT Clinical Trials www.oct-clinicaltrials.com

CONTACTAnna Yanaeva Business Development Associate

ADDRESS 8/2 Bolshaya Moskovskaya, let-A, suite 4-1, Saint Petersburg, 191002 Russia

TELEPHONE +7 (812) 449 86 34

FAX +7 (812) 449 86 35


YEAR FOUNDED2005

COMPANY PROFILE

OCT Clinical Trials is a privately owned leading mid-size full-service contract research organization operational since 2005. With team of 120 professionals and operations in Russia, Ukraine, Bulgaria, Belarus, Latvia, Lithuania and Estonia, OCT has completed more than 180 projects in Phase I-IV clinical trials, as well as pre-clinical and bioequivalence studies. With more than 120 research professionals, OCT provides drug development services to its clients. OCT clients and partners include pharmaceutical, biotechnology, medical device and non-for-profit organizations.

We advance a product through development and approval on time and with confirmed by track record world-class quality. Our experienced team delivers within settings of full clinical trial programs or standalone services like medical writing, consultancy, monitoring, data management/statistics.

OCT expertise includes more than 180 projects in a wide range of therapeutic areas, including but not limited to oncology, cardiology, pediatrics, endocrinology, ophthalmology and others.

MANAGEMENT

Dmitry Sharov, PresidentElena Startseva, Head of Business DevelopmentIrina Petrova, Clinical Operations Director


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

Opsona Therapeutics Ltd www.opsona.com

CONTACTSDr Martin Welschof Chief Executive Officer

Anne Jensen Executive Assistant

ADDRESS 2nd Floor Ashford House Tara St Dublin 2 Ireland

TELEPHONE +353 860 205616

FAX +353 167 78949


YEAR FOUNDED2004

FINANCIAL SUMMARY

Biotechnology Company0-20 EmployeesPrivate CompanyLatest Round of Funding – C RoundFunding total to date – $95M

COMPANY PROFILE

Opsona Therapeutics is a leading immunology drug development company, focused on novel therapeutic approaches to key targets of the innate immune system associated with a wide range of major human diseases, including autoimmune and inflammatory diseases, with specific focus on Solid Organ transplantation and Oncology.

The company was founded in 2004 by three world-renowned immunologists at Trinity College in Dublin.

Opsona’s lead product, a fully humanized monoclonal IgG4 antibody (OPN-305) targeting Toll-like-receptor-2 (TLR2) has demonstrated activity in a number of preclinical models and has been tested in a Phase I clinical trial in healthy volunteers. The company has initiated a three-part multi-centred, double blinded and placebo controlled Phase II clinical study to evaluate the safety, tolerability and efficacy of OPN-305 in renal transplant patients at high risk of Delayed Graft Function (DGF) as the first clinical indication for the development of OPN-305 of which the first part has been completed successfully. OPN-305 has obtained EMA and FDA orphan drug status in Solid Organ Transplantation.

MANAGEMENT

Dr Bernd Seizinger, Chairman Dr Martin Welschof, CEO Mary Reilly, VP Pharmaceutical Development & Operations Prof Luke O’Neill, Co-Founder, Director and CSO Conor Dalton, Finance Director Dr Robert M Miller, Consultant Chief Medical Officer


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

perora GmbH www.perora.com

CONTACTDirk Vetter, PhD Managing Director

ADDRESS Im Neuenheimer Feld 518 69120 Heidelberg Germany

TELEPHONE +49-6221-4344733

FAX +49-6221-4344739


YEAR FOUNDED2013

FINANCIAL SUMMARY

Seeking Ser A Funding

COMPANY PROFILE

PERORA is a start-up focused on creating a new platform for the treatment of obesity and diabetes type II.

PERORA was seed-financed in 2013 by High-Tech Gründerfonds (Bonn, Germany).

PERORA has achieved in vivo validation and is pushing its program towards clinical studies to obtain medical device class IIb approval.

MANAGEMENT

Dirk Vetter, PhD, Managing DirectorKristina Schmidt, PhD, COO/CAO


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

Pherecydes Pharma www.pherecydes-pharma.com

CONTACTGuy-Charles Fanneau de La Horie

ADDRESS Pherecydes Pharma 102 avenue Gaston Roussel Bâtiment Pasteur 93230 Romainville FRANCE

TELEPHONE +33 (0)6 07 66 61 09

FAX +33 (0)1 48 40 55 32

EMAIL guy-charles.la.horie78 @wanadoo.fr

YEAR FOUNDED 2006

FINANCIAL SUMMARY

Pherecydes Pharma is currently in the process of raising a round B tour.

COMPANY PROFILE

Pherecydes Pharma is a biotechnology company that has integrated evolutionary medicine in the development of antibacterial treatments. Thanks to its bacteriophage expertise and mastery of phage therapy, the company develops drugs against all types of antibiotic resistant bacteria. Moreover, these products can adjust to germs changing over time. The first two drug candidates enter Phase IIb clinical studies in H2 2014.

MANAGEMENT

Jérôme Gabard PhD, CEOFlavie Pouillot PhD, CSOGuy-Charles Fanneau de La Horie, DVM MBA


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

CONTACTSAmir Weisberg CEO

Noam Emanuel CTO

Malka Reichart, PhD BD Manager

ADDRESS 20 Hamagshimim St., P.O.Box 7126, Petach-Tikva Israel 49170

TELEPHONE +972.74.719.5700 M. +972.54.490.0474

FAX +972-74-719-5718


YEAR FOUNDED2008

FINANCIAL SUMMARY

PolyPid is a private company.

COMPANY PROFILE

PolyPid is an innovator of proprietary medical devices and pharmaceutical drug delivery solutions: our medical devices uniquely protect implanted devices from early resorption over significant periods of time while our pharmaceutical solutions optimize drug delivery by enabling a controlled, constant and prolonged release of any drug, regardless of drug size or characteristic.

PolyPid’s medical device flagship, BonyPid™, is an antibiotic-loaded bone substitute that supports bone recovery. BonyPid™ is currently in advanced clinical trials in open bone fractures. BonyPid™ is also PolyPid’s solution to many dental ailments. Clinical trials of BonyPid™ in dental applications are expected to start on Q2 2014.

PolyPid’s pharmaceutical arm is engaged in the development of drug coating platforms for local, controlled and prolonged delivery of drugs directly to treatment sites. PolyPid formulation has proven the effectiveness in releasing small molecules, peptides proteins and nucleic acids based drugs and is now concentrated in the development of products releasing growth factors and anticancer drugs.

Market Potential of first products: BonyPid™ may replace the currently used bone fillers, due to its ancillary antibacterial activity.

PolyPid is seeking partners for strategic and commercial collaboration.

MANAGEMENT

Amir Weisberg, CEO Noam Emanuel, Ph.D., CTO Shaun Marcus, CFO Jack Eitan Kyiet, COO

PolyPid www.polypid.com


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

PolyThericswww.polytherics.com

CONTACTSJohn Burt CEO

ADDRESS The London Bioscience Innovation Centre 2 Royal College Street London NW1 0NH

Antitope: Babraham Research Campus Babraham Cambridge CB22 3AT

TELEPHONE +44 (0) 207 691 4927 Antitope: +44 (0) 1223 496190


YEAR FOUNDED 2001

FINANCIAL SUMMARY

£13.5 million equity financing round (July 2013) in connection with the acquisition by PolyTherics of Antitope

Previous financing rounds in 2007, 2009 and 2011 raised an aggregate of £10 million.

PolyTherics investors include Imperial Innovations, Invesco Perpetual, ProVen Growth & Income VCT, Oxford Technology VCTs, Mercia Funds, Capital Fund & Advantage Enterprise & Innovation Fund

COMPANY PROFILE

PolyTherics provides technology solutions to enable the development of better biopharmaceuticals and offers a portfolio of proprietary and complementary technologies and services to address key needs in biopharmaceutical development.

PolyTherics’ portfolio of services and technologies includes proprietary site-specific conjugation technologies and novel polymers for optimising the therapeutic properties of biopharmaceuticals and through its Cambridge, UK-based subsidiary, Antitope, services for protein immunogenicity assessment and antibody and protein re-engineering technologies are delivered.

Core offerings include:ThioBridge™ - site-specific conjugation for ADCs TheraPEG™ – site-specific pegylation chemistry PolyPEG™ – low viscosity polymer as alternative to PEG for half-life extension

Antitope:EpiScreen™ – ex vivo assessment of immunogenicity for protein and antibody therapeutics Composite Human Antibody™ & Composite Protein™ – protein engineering for humanization and deimmunisation Composite CHO™ – efficient manufacturing cell-line development service

MANAGEMENT

John Burt, Chief Executive Officer Julian Smith, Chief Financial Officer Matthew Baker, Chief Scientific Officer Sally Waterman, Senior VP, Corporate Development Neil Butt, VP, Business Development Donna Hackett, VP, IP, Commercial & Legal Affairs Antony Godwin VP, Chemistry Tim Jones, VP, Biology Jeff Edwards, VP, Alliance Management


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

Prexton Therapeutics www.prextontherapeutics.com

CONTACTFrançois Conquet CEO

ADDRESS 14, Chemin des Aulx 1228 Plan les Ouates Geneva Switzerland

TELEPHONE +41 79 822 67 25

EMAIL francois.conquet @prextontherapeutics.com

YEAR FOUNDED 2012

FINANCIAL SUMMARY

Seed investment from Merck Serono Ventures

COMPANY PROFILE

Prexton is a spin-off of Merck Serono and develops small molecules for Parkinson’s disease. The lead compound is a mGluR4 PAM and is 6 months from the clinic.

MANAGEMENT

François Conquet, CEO Peter Hongaard Andersen, Chairman of the BoD Florian von Raison, Chairman of the SAB


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

Probiodrug www.probiodrug.de

CONTACTHendrik Liebers CFO

ADDRESS Weinbergweg 22 D-06120 Halle (Saale) Germany

TELEPHONE +49 345 5559900

FAX +49 345 5559901


YEAR FOUNDED 1997

COMPANY PROFILE

Probiodrug has developed a novel therapeutic approach against Alzheimer`s Disease (AD), based on inhibiting the enzyme Glutaminyl Cyclase (QC).

In AD, QC catalyzes the formation of the pyroglutamic versions of amyloid beta (pGluABeta) - species with increased neurotoxicity, prolonged half-life and increased aggregation propensity. They account for about 50% of the whole ABeta deposited in the typical AD plaques. Inhibition of QC in several AD animal models has been shown to reduce pGluABeta and improve cognitive abilities.

The lead molecule of Probiodrug, PQ912, is the first QC inhibitor in clinical trials. Clinical data have been presented at the AAIC 2013. Probiodrug is preparing PQ912 for a phase 2 development. A pipeline of followers and back up molecules is progressed in parallel.

The main program is paralleled by an anti pGluABeta antibody approach.

Probiodrug is private and backed by major institutional and pharma investors.

MANAGEMENT

Dr Konrad Glund, CEO Hendrik Liebers, CFO Dr Inge Lues, CDO Dr Ronald Black, CMO


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

ProFactor Pharma Ltd www.profactorpharma.com

CONTACTRichard Cruse CEO, CFO

ADDRESS BioCity Scotland, Bo’ness Road Newhouse ML5 1UH Scotland

TELEPHONE +44 1698 537855

EMAIL richard.cruse @profactorpharma.com

YEAR FOUNDED2009

FINANCIAL SUMMARY Funding to Date £1M

COMPANY PROFILE ProFactor Pharma Ltd (PFP) was established to commercialise and supply recombinant blood factors for the treatment of haemophilia to a severely undersupplied world market, leading to the development of a significantly profitable biopharmaceutical business. Haemophilia is treated with clotting factors sourced either from recombinant manufacture or from human plasma.

PFP’s lead product is recombinant human Factor VIII (rhFVIII) – probably one of the most expensive compounds in the world – gram for gram more expensive than diamonds, gold, oil and most other drugs. Current sales of rhFVIII are US$4.9BN (2012), and the market is constantly growing.

According to the World Health Organisation (WHO), 75% of the global haemophilia patient population receive inadequate or no treatment at all. The reason for this is two-fold: treatment is expensive and, perhaps more importantly, there is just not enough product to go around. Patients not properly treated are typically hospitalised 3-4 times per year at a not inconsiderable cost.

The PFP vision is to create a sustainable and profitable business, using advanced biologics production technology, delivering currently undersupplied recombinant human blood factors, making safe treatment available to a greater proportion of the world’s haemophiliac population and increasing the opportunity for prophylactic use.

MANAGEMENT

Richard Cruse, CEO, CFO Dr Ian Garner, Chief Science OfficerBruce Vernon, Director of Regulatory Affairs & QADr David Brown, Non-Executive ChairmanProf John H McVey, Chief Scientific Advisor


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

Scancell Holdings Plc.www.scancell.co.uk

CONTACTDr Richard Goodfellow Chief Executive Officer

ADDRESS Scancell Ltd Dept Clinical Oncology City Hospital Hucknall Road Nottingham NG5 1PB

TELEPHONE +44 (0) 115 823 1863

FAX +44 (0) 115 823 1863


YEAR FOUNDED1997

COMPANY PROFILE

Scancell is listed on AIM. It has a market calitalisation of £80m and is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms.

Scancell’s first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma. SCIB1 is dellivered as a DNA plasmid using Ichor’s TriGrid electroporation device. Clinical trials have shown that SCIB1 produced a compelling melanoma-specific T cell response and highly promising survival trend.

The profile suggests that SCIB1 has a place both in combination with the check point inhibitors and as monotherapy for earlier stage disease.

Scancell has several other ImmunoBody vaccines in the pipeline targeting other well know cancer targets.

Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4 T cells and that destroy tumours without toxicity.

The Moditope® platform deploys certain tumour-¬€associated peptide epitopes as immunotherapeutic agents to overcome self-¬€tolerance and eradicate tumour cells, with no requirement for blockade inhibitors

The Moditope® platform has been exemplified by the lead product Modi-1 which exhibits potent anti-¬tumour efficacy in in vivo therapeutic models. Efficacy has been observed even against aggressive, established tumours, improving survival rates.

MANAGEMENT

Professor Lindy Durrant, Joint CEO Dr Richard Goodfellow, Joint CEO


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

Selvita www.selvita.com

CONTACTPaulina Wolanin PR, Media

ADDRESS ul. Bobrzynskiego 14 30-348 Krakow Poland

TELEPHONE +48 12 297 47 00

FAX +48 12 297 47 01


YEAR FOUNDED2007

FINANCIAL SUMMARY

Selvita is a Polish drug discovery company listed in Warsaw with a market capitalization of $ 35M and FY13 revenues of $7 M. The revenues from partnering contracts combined with services business and grant funding has allowed the company to report positive EBITDA in Q4 for the first time in the corporate history and zero cash-burn for 2013.

Selvita has invested $11.3 M in own R&D projects over 2007-2013. More than $19 M has been secured in grants for research. Important partnering deals: in September 2013 with US company - H3 Biomedicine (up-front, research funding plus milestones), and in October 2013 with Merck Serono (research funding plus milestones).

COMPANY PROFILE

Selvita is a Polish biotechnology company engaged in the discovery and development of breakthrough medicines to treat oncology, CNS and autoimmune disorders, as well as provision of drug discovery services.

It was established and 2007 and currently employs 178 scientists, including 58 PhDs. Selvita has currently several projects at early or late discovery stage and is expected to move its first candidates to the clinic in 2014.

The most advanced programs are entering pre-clinical development: SEL24, a Pim kinase inhibitor, with multiple indications in hematopoietic tumors, SEL120, focused on first-in-class small molecule inhibitor of CDK8 and SEL103 for the symptomatic treatment of Alzheimer’s disease.

Other innovative projects currently at discovery stage include SEL201, aimed at development of inhibitors of MNK1/2 kinases in cancer, SEL141, an early stage discovery program of a series of DYRK1A kinase inhibitors with therapeutic potential in the treatment of tauopathies, including Alzheimer’s disease and Down syndrome, and SEL212, NALP3 inflammasome modulators for the treatment of autoinflammatory and autoimmune disorders.

The service part of the company delivers a comprehensive panel of products and solutions targeted at lowering the cost of, and accelerating, the introduction of new drugs to the market. Selvita offers its clients drug discovery support at every stage of the early discovery phase up to preclinical research.

Selvita has experience in several areas of drug discovery and development, and offers the following types of projects:

– Integrated drug discovery projects – Chemistry services (contract synthesis, pathway design and optimization, scale-up, physicochemical

analyses) – Biology services, (assay development, ADME, toxicity studies, DMPK, PK/PD) – Advanced protein modeling solutions.

MANAGEMENT

Paweł Przewiezlikowski, Chief Executive Officer Boguslaw Sieczkowski, Executive Vice President, Chief Operating Officer Krzysztof Brzozka, Executive Vice President, Chief Scientific Officer Mirosława Zydron, Member of the Management Board, Director of Chemistry Department Milosz Gruca, Member of the Management Board, Director of Biology Department Sebastian Kwasny, Member of the Management Board, Director of Bioinformatics Department


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

SIRION Biotech www.sirion-biotech.com

CONTACTSDr Christian Thirion Managing Director

Dieter Lingelbach Managing Director

ADDRESS Am Klopferspitz 19 82152 Martinsried near Munich Germany

MUNICH ∙ TOKYO ∙ NEW HAMPSHIRE

TELEPHONE +49-89-700-961-99-0

Dr. Christian Thirion +49-151-240-900-73

Dieter Lingelbach +49-176-646-25439

FAX +49-89-700-961-99-8


YEAR FOUNDED 2007

FINANCIAL SUMMARY

18 staff> €1.2 Mio SalesGrowing 30-50 % p.a.

COMPANY PROFILE

SIRION Biotech supplies a wide variety of viral vectors of highest sophistication for gene function research, development of gene therapies and better vaccine applications.

The company was founded in 2007 with the goal to shift the paradigm in viral vector technologies and supplies

• Viral vectors represent a new class of compounds revolutionizing the study of genes and allowing for gene therapy and more effective vaccines

• Viral vector technologies were still in their infancy then and were only provided by academia and in-house groups. Specialty suppliers did not exist yet that focused on advancing the technologies and making a broad range of viral vector types and related cell models broadly available

SIRION Biotech, 6 years later, has been shifting the paradigm, it…

• provides all major vector types, adenovirus, adeno-associated virus (AAV) and lentivirus within a matter of weeks

• at highest titers and in quantities required for preclinical and animal testing.

• viral vectors can be synthesized from human pro-duction cell lines allowing for highest safety standards

• GMP-quality standards available soon

• Novel serotypes like Ad19a have been developed to enable new options for cell transductions in large animals and humans

• ~ 1.000 ready-made products & kits

• easily accessible in key markets, Munich, Tokyo, New Hampshire, shipments from Munich are a matter of days

Single viral vectors and cell models are undergoing preclinical trials on behalf of SIRION.

MANAGEMENT

The company operates with more than 18 staff of which 8 have academic degrees (PhD. / Masters). There are two acting Managing Directors. Dr. Christian Thirion holds a Ph.D. from the Munich Gene Center. Christian is a renowned speaker on cellular analysis and modelling. Dieter Lingelbach is a Fulbright Scholar and has a Booz, Allen & Hamilton background; he was many years with Roche and Morphosys. The company is closely connected with professionals from within the Life Science industries in Tokyo, Oxford, UK, New Hampshire and Israel.


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

Synthena AGwww.synthena.com

CONTACTDr Wolfgang Renner Chief Executive Office

ADDRESS Freiestrasse 3 3012 Bern Switzerland

TELEPHONE +41 79 219 96 70


YEAR FOUNDED 2012

FINANCIAL SUMMARY

Raised CHF 10 million is series A financing

COMPANY PROFILE

Synthena AG is a privately held, Swiss biopharmaceutical company focused on the development of new tricycloDNA based oligonucleotide drugs for the treatment of severe neuromuscular diseases. Its lead product SYN01 is in preclinical development for Duchenne muscular dystrophy, where it has shown unprecedented efficacy in restoring skeletal muscle, respiratory, cardiac and cognitive functions in different animal models. Further research programs are ongoing in Spinal Muscular Atrophy, Steinert’s disease, and Pompe disease.

MANAGEMENT

Wolfgang Renner PhD, Chief Executive Officer – holds a PhD degree in biotechnology from ETH Zürich since 1995. Right after his PhD he co-founded Cytos Biotechnology AG and was CEO of Cytos until 2011, 9 years of which as a public company. During this period he built an integrated discovery and development platform which yielded 10 clinical programs of which 4 are currently in active phase I to phase IIb development; licensed 5 products to major pharmaceutical companies; raised over CHF 270 mio and generated over CHF 100 mio in aggregated revenues. Wolfgang Renner is a member of the executive committee of the foundation council of the Swiss

National Science Foundation.

Branislav Dugovic PhD, Chief Technology Officer – studied chemistry at the Slovak technical university since 2005. After performing post-doctoral work at the Freie Universität Berlin he moved to University of Bern in 2009, where he further developed and expanded the bicyclo- and tricyclo-DNA molecular platforms.

Adrian Häberli PhD, Head Quality Control – studied chemistry at the University of Bern and graduated 2001 in the subject of oligonucleotide chemistry. Following his postdoctoral studies in Canada he held positions at Interlabor and ZLB Behring. In 2005 he became head of the laboratory unit Pharmacopoeia and scientific expert for forensic chemistry at the Swiss Medicines Control Agency Swissmedic.


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

Synthetic Biologics, Inc. www.syntheticbiologics.com

CONTACTSJeffrey Riley CEO

C. Evan Ballantyne CFO

ADDRESS 155 Gibbs Street, Ste. 412 Rockville, MD 20850 USA

TELEPHONE (734) 332-7800

Jeffrey Riley, CEO M: (619) 309-7661

C. Evan Ballantyne M: (401) 215-6003

FAX (734) 332-7878

EMAIL [email protected] [email protected] eballantyne @syntheticbiologics.com

YEAR FOUNDED 2001

COMPANY PROFILE

Synthetic Biologics, Inc. (NYSE MKT: SYN) is a biotechnology company focused on the development of product candidates for serious infectious and other diseases. Synthetic Biologics is developing oral treatments targeting archaea, a non-bacterial intestinal form of life increasingly associated with chronic diseases such as irritable bowel syndrome (IBS), obesity and type 2 diabetes, an oral biologic to protect the gastrointestinal microflora from the effects of IV antibiotics for the prevention of C. diff infection, a series of monoclonal antibodies (mAbs) for the treatment of Pertussis and Acinetobacter infections, and a biologic targeted at the prevention and treatment of IBS. In addition, the Company is developing an oral estriol drug candidate for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS.

MANAGEMENT

Jeffrey Riley, CEO, President and Director C. Evan Ballantyne, CFO John Monahan, PhD, Executive Vice President, Research & Development Michael Kaleko, MD, PhD, Senior Vice President, Research & Development Joseph Sliman, MD, MPH, Senior Vice President, Clinical & Regulatory Affairs Lewis Barrett, Senior Vice President, Commercial Strategy


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

TiGenix www.tigenix.com

CONTACTEduardo Bravo CEO

ADDRESS Romeinse straat 12/2 3001 Leuven Belgium

TELEPHONE +32 16 396060

FAX +32 16 397970


YEAR FOUNDED 2000

FINACIAL SUMMARY

TiGenix is listed on NYSE Euronext (TIG). Reference shareholders include Grifols, Roche and Novartis; Market cap: Around 140M

COMPANY PROFILE

TiGenix NV (NYSE Euronext: TIG) is a leading European cell therapy company with one product on the market and a strong clinical stage pipeline of adult stem cell programs. The company’s lead product, ChondroCelect®, for cartilage repair in the knee, is the first product to be approved and obtain national reimbursement in Europe. ChondroCelect is currently on the market in Belgium, the Netherlands, Spain, the UK and Finland and benefits from full national reimbursement in 3 of these countries.

TiGenix’s stem cell programs are based on a validated platform of allogeneic expanded adipose-derived stem cells (eASCs) targeting autoimmune and inflammatory diseases. Built on solid pre-clinical and CMC packages, they are being developed in close consultation with the European Medicines Agency. TiGenix’ eASC pipeline comprises 3 clinical stage assets:– Cx601: In European Phase III for the treatment of fistulising Crohn’s. Positive pre-IND for US development

completed– Cx611: Phase IIa completed in RA– Cx621: Phase I completed

TiGenix is based out of Leuven (Belgium), and has operations in Madrid (Spain), and Sittard-Geleen (the Netherlands). For more information please visit www.tigenix.com

MANAGEMENT

Eduardo Bravo, Managing Director and CEOClaudia D’Augusta, Chief Financial Officer (CFO)Wilfried Dalemans, Chief Technical Officer (CTO)María Pascual, VP Medical Affairs, Clinical Operations and Regulatory


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

ugichem GmbH www.ugichem.at

CONTACTHolger Bock PhD Chief Executive Officer

ADDRESS Mitterweg 24 A-6020 Innsbruck Austria

TELEPHONE +43 512 282285 10

FAX +43 512 282285 11


YEAR FOUNDED 2003

FINANCIAL SUMMARY

Funding to date: € 11m Investors: BioScience Venture Group, V+ investment fund, private investors The company is seeking new investors alongside existing shareholders for the closing of a new financing round of € 10m in Q3/2014.

COMPANY PROFILE

ugichem is a preclinical stage company developing innovative antisense therapeutics called Ugimers®.

Antisense drugs are assessed to become the 3rd major drug discovery engine after monoclonal antibodies and small molecules. This is documented by a strongly increasing number of licensing deals between leading antisense and big pharmaceutical companies with up to three-digit US$ up-front payments during the past 12 months.

At present, the established antisense concepts are very successfully used for diseases of the liver and in tumor tissues but exhibit only a limited therapeutic window for diseases in other organs.

The Ugimer breakthrough-advantage is the tissue- and cell selective developability, providing a significantly improved therapeutic window for inflammatory/autoimmune diseases, cancer and degenerative diseases outside the liver and tumors.

Ugimer advantages in detail:1. Cell and tissue specific developability2. High therapeutic potential for anti-inflammatory applications in – Immune cells, kidney, muscles, joints, spleen …3. Superior safety profile – No dose limiting toxicity due to disproportional liver accumulation – Low risk of unspecific immune system stimulation

MANAGEMENT

Holger Bock PhD, CEOThomas Lindhorst PhD, CSOJürgen Soutschek PhD, CTO


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

VolitionRx www.volitionrx.com

CONTACTSMr Cameron Reynolds CEO

Dr Mark Eccleston Collaborations Manager

ADDRESS 20A Rue Du Seminarire, Namur BE-5000 BELGIUM

TELEPHONE +44 (0) 1353 771 312

FAX +32 (0) 81 72 56 51


YEAR FOUNDED 2010

FINANCIAL SUMMARY

Market Cap: $28.03 M

Price: $2.40 (at 04.01.14)

Shares Issued: 11.68 M

Cash: $889 K +$485 K grant (at 31.12.2013)

COMPANY PROFILE

VolitionRx is focused on developing blood-based diagnostic tests for early detection of cancer. Colorectal cancer screening is potential blockbuster application (estimated total market $4Bn). Early detection allows more effective intervention and improves patient outcome whilst affordable and accessible cancer diagnostics are seen as a critical step in addressing an increasingly unsustainable burden on healthcare budgets. Volition’s tests are based our proprietary Nucleosomics® technology which identifies and quantifies nucleosomes (protein/DNA complexes released from dying cells) in the bloodstream – using established, simple immunoassay technology. VolitionRx’s goal is to make the tests readily available and as simple to use, for both patients and doctors, as existing diabetic and cholesterol blood tests.

VolitionRx’s research and development activities are currently centred in Belgium as the company focuses on bringing its diagnostic products to market first in Europe, then in the US and ultimately, worldwide. We have a pivotal 4800 subject clinical trial underway in colorectal cancer with the University of Hivdovre (Denmark), (based on pilot data with 86% sensitivity and 86% specificity for colon cancer) which will support CE marking in the EU. An 11000 subject prospective study is expected to commence in Q2 2014. US trials are expected to begin by Q3 2014.

MANAGEMENT

Cameron Reynolds, CEO Martin Faulkes, Chairman Malcolm Lewin, Chief Financial Officer Jason Terrell, Chief Medical Officer Jake Micallef, Chief Scientific Officer Mark Eccleston, Collaborations Manager Tom Bygott, Sales and Marketing Director


PANIESORGANISERS

WELCOM

ESPEAKERS

t back :: next u

WISE www.wisebiotech.com

CONTACTLuca Ravagnan CEO

ADDRESS Italian Headquarters: WISE Srl Piazza Duse 2 20122 Milano Italy

Independent German Branch: WISE Srl Robert-Rössle-Strasse 10 13125 Berlin Germany

TELEPHONE +39 333 765 7189


YEAR FOUNDEDItalian Headquarters: 2011Independent German Branch: 2014

FINANCIAL SUMMARY

The company was founded in 2011 with a first Angel investment of €80,000 by Agite! SpA. In 2012 it raised over 500,000 in seed investment (€250,000 from Veneto Nanotech ScpA) and grants.

In November 2013 the company has concluded a seed-round of €1M to advance the development of its first product aimed at the spinal cord stimulation market. High-Tech Gründerfonds, Atlante Seed and b-to-v Partners co-led the round and were joined by the existing investor Agite!.

COMPANY PROFILE

WISE has the mission to develop and market a new generation of electrodes for neuromodulation for the treatment of neurologic diseases. The electrodes are produced through a proprietary innovative technology, which allows the metallization of stretchable polymers. The obtained electrodes are highly biocompatible, unbreakable, minimally invasive and cheaper than existing products.

The activity of WISE is based on an innovative technology, namely the “Supersonic Cluster Beam Implantation” (PCT/EP2011/054903), which consists in embedding metal nanoparticles inside a preformed elastomeric base in order to form a conductive metal-polymer skin on its surface. The electrodes obtained with this technique are strongly attached to the polymer, resist without electrical failure to extensive deformations of the polymer, such as bending and stretching, and have very good performances in terms of biocompatibility.

MANAGEMENT

Luca Ravagnan, CEO Mario Zanone Poma, Chairman Sandro Ferrari, R&D Manager Giulia Salzano, Administration Manager



WELCOM

ESPEAKERS

Supporting Organisations

t back :: next u

www.biodeutschland.org

As the sector association of the biotechnology industry, BIO Deutschland has set itself the objective of supporting and promoting the development of an innovative economic sector based on modern biosciences.

The Berlin-based association currently has over 300 members. It is run by a board of ten members consisting of CEOs and managing directors of biotechnology companies, as well as directors of BioRegions. This committee comprehensively represents the various fields in the sector.

The member companies and their experts are organised in working groups that deal with the following topics: finance and taxation; licences and technical contracts; regulatory matters; innovation and entrepreneurship; HR; German-US cooperation; health policy; competition and regulatory policy; technology transfer; and PR. Using a wide range of political initiatives, BIO Deutschland lobbies for improvements to the legal parameters for innovative small and medium-sized enterprises.

BIO Deutschland is Germany’s biotechnology sector representative at the European association, EuropaBio, in Brussels. BIO Deutschland also works closely with other biotech organisations in Europe and the USA in order to lobby for the interests of the sector in an internationally coordinated way. The association is also very active in a broad range of events with the aim of providing biotechnology with a platform for discussion and interaction.

BIO Deutschland Am Weidendamm 1a 10117 Berlin

Tel: +49-30-726 25 130Fax: +49-30-726 25 138E-Mail: [email protected]

Bio Deutschland



WELCOM

ESPEAKERS


t back :: next u

www.biotechgate.com

Your source for life science companies and licensing information.

If you are about to negotiate a licensing deal between a Biotech and a Pharma company. Or you are looking for a big Pharma company to out-license your Biotech product. Or you are active in the medical technology (Medtech) sector and just want to identify potential cooperation partners or customers. Or you are an investor looking for investment opportunities - or you just want to know about historical financing rounds and valuations in the life sciences, Biotech, Pharam and medical device field. This portal can solve all of these problems - and even more.

Biotechgate



WELCOM

ESPEAKERS


www.biotop.de

BioTOP Berlin Brandenburg is the central contact and coordination office for all issues concerning biotechnology in the German capital region.

It is our objective to coordinate all regional activities in biotechnology by networking with all key players and to initiate specific projects in order to turn Berlin-Brandenburg into a globally leading life science cluster.

The services provided by BioTOP include:

• Technology transfer science - industry

• Initiation and support of networks

• Support for technology-oriented start-ups

• Funding support for innovative projects

• Providing information on biotechnology

• Building and coordination of scientific and interdisciplinary networks

• Establishing contacts between experts from all disciplines

• Design and organization of events

• Public relations work for the biotech region Berlin-Brandenburg

For more information, including a database with comprehensive profiles of all companies and scientific work groups, please visit our website at www.biotop.de.

Dr. Kai Bindseil BioTOP Berlin-Brandenburg Fasanenstr. 85 10623 Berlin - Germany

Tel: +49 30 318 622 11Fax + 49 30 318 622 22

BioTOP Berlin-Brandenburg

t back :: next u



WELCOM

ESPEAKERS


www.citigatedr.co.uk

Citigate Dewe Rogerson is the leading international consultancy specialising exclusively in financial and corporate communications across the UK, Europe, North America and Asia.

Citigate has a dedicated Pharma & Biotech team with more than 60 years combined experience in the sector and a unique mix of skills: corporate and financial PR and investor relations, finance, journalism and academic science. The team provides sector expertise and forms an integrated part of Citigate Dewe Rogerson, benefiting from the company’s overall strength and from the cross-fertilisation of ideas across sectors.

The Citigate Pharma & Biotech team has an established track record in working with biotechnology companies at all stages in development. As well as core skills in financial calendar work, transactions support, financial PR and media relations, the team has extensive experience in branding, design and new media consultancy. Recent clients include global top-five biotechs, listed companies in the UK and Europe, and numerous emerging businesses in the UK, France, Germany, the Netherlands, and Scandinavia.

Citigate’s Pharma & Biotech team has been involved in major corporate transactions such as IPOs, other public and private fundraisings, and M&As. We have advised on a number of IPO transactions across Europe including; METabolic EXplorer (Euronext Paris - €52 million), Algeta (Oslo Stock Exchange - €30 million), Santhera Pharmaceuticals (SWX – CH88.5 million), ThromboGenics (Euronext Brussels - €35 million), Hutchison China MediTech (AIM - £40 million), Zentiva (LSE and PSE – US $211 million), Arpida (SWX - €63 million), Inion (LSE - £35 million), TopoTarget (CSE - €30 million), BioFusion (AIM - £8.2 million) and ExonHit (Alternext - 7.3 million).

Citigate Dewe Rogerson3 London Wall BuildingsLondon WallLondon EC2M 5SY

Tel: +44 (0)-207-638-9571

Citigate Dewe Rogerson

t back :: next u



WELCOM

ESPEAKERS

t back :: next u


www.flandersbio.be

FlandersBio is the networking organisation for the life sciences sector in Flanders (Belgium) – with currently more than 280 members. FlandersBio supports and facilitates the sector’s sustained development to ensure that it remains a strong driver of economic growth in the region. FlandersBio can assist you in finding your partner within the network of Flemish life sciences actors, e.g. life sciences companies, Venture Capitalists, research organizations, subsidy agencies, etc.

FlandersBio officesJean-Baptiste de Ghellincklaan 13 bus 01029051 GENTBELGIUM

Tel.: +32 9 241 80 41Fax: +32 9 241 80 [email protected]

FlandersBio



WELCOM

ESPEAKERS

t back :: next u


FreeMind www.freemindconsultants.com

FreeMind is a consulting group whose goal is to assist its clients in maximizing their potential to receive funding from non-dilutive sources. Established in 1999, FreeMind is the largest consulting group of its kind with over 400 active clients, academics and Industry alike. FreeMind’s proven long-term strategic approach has garnered its clients over 1.5 billion dollars to date.

Our expertise in applying for grants and contracts extends throughout every government mechanism open to funding the life sciences including all NIH institutes, DoD, NSF, FDA, CDC, BARDA, etc., as well as private foundations such as Michael J Fox, Bill and Melinda Gates and Susan G Komen.

FreeMind’s knowledgeable and experienced team of Analysts and Project Managers are dedicated to guiding its clients non-dilutive funding efforts from identification of the most suitable opportunity through to submission and subsequent award. Our team of experts will assist our clients in making non-dilutive funding a key tool in their long-term financial strategy.

Tel: (617) 648-0340 Fax: (617) 904-1767 Email: [email protected]

BostonFreeMind Group423 Brookline Ave. #124Boston, MA 02215

Washington DCFreeMind Consultants4094 Majestic lane # 269Fairfax, VA 22033

JerusalemFreeMind GroupHi - Tech CenterHebrew UniversityJerusalem 95702Israel



WELCOM

ESPEAKERS

t back :: next u


[LSE] – The European Life Sciences Business Web Portal.

Life-Sciences-Europe.com is your doorway to the life sciences in Europe and Israel!Life-Sciences-Europe.com updates worldwide visitors about recent developments in the life sciences industry in Europe. [LSE] tries to cover all kinds of information – from persons to products. Content is included just because of relevance and inclusion is not related to any payments or advertising. Usage is unrestricted and free, without the need for user registration and accordingly no user data will be sold or marketed!

Organisations covered[LSE] includes universities and research organisations, industrial companies and assocations as well as governmental bodies. Software companies, public relations companies, advisors and financial companies active in European markets are also covered, the same goes for regulatory and other governmental institutions.

Free & Up-to-DateTo sum up: [LSE] is your information doorway to the life sciences in Europe and Israel. Free, up-to-date, structured, non-biased, easy-to-use and very powerful – 100% Made in Germany.

[iito] Business IntelligenceMarcus LippoldSüderstr. 428199 BremenGermany

Phone: +49-421-9889173Fax: +49-421-587038E-Mail: [email protected]

Life-Sciences-Europe.com www.life-sciences-europe.com[iito]



WELCOM

ESPEAKERS

t back :: next u


www.lifesciences.instinctif.com

Instinctif Partners is an international business communications consultancy. With a track record of delivering truly creative programmes, the Life Sciences practice focuses on enhancing the value proposition for companies seeking investment, partnerships or customers. Our core skill is working with clients to communicate the value of their science and innovation to key stakeholders through the most relevant channels: crafting communications solutions that showcase each company, product or technology. Specifically, we are unique in offering specialist expertise seamlessly across corporate, financial, healthcare and marketing communications with outreach programmes to media, industry, professional, public, financial and investment communities. Our service offering covers all communications disciplines including strategic counsel, PR, IR, media relations, public affairs, crisis communications, internal communications, marketing, advertising, copywriting, design, research and event management. Our globally integrated and dedicated life sciences team serves clients around the world from our bases in London, Manchester, Munich, Boston, Melbourne and Sydney.

For more information please visit www.lifesciences.instinctif.com

INSTINCTIF Partners



WELCOM

ESPEAKERS

t back :: next u


Life Science Austria www.lifescienceaustria.at

Life Science Austria - LISA - is a program acting as a hub for people from all over the world who are interested in the life science sector in Austria. Together with its associates in the Austrian regions, LISA is the first point of contact for anyone with questions about scientific collaboration, setting up an operation, or funding and sponsoring projects and businesses in Austria.

Working with all existing life science clusters in the Austrian regions – ecoplus, human.technology.styria, Life Science Austria Vienna Region, Health Technology Cluster, and Life Science Cluster Tirol - LISA is able to build on their expertise and services. The aims of LISA and its partners are: contribute to the success of life science enterprises in Austria by helping to introduce scientific discoveries to the market, assist in the search for funding, and provide general business consultancy and support to ensure healthy commercial development.

Austria Wirtschaftsservice GesmbH (aws), is responsible for running this program on behalf of the Austrian Federal Ministry of Economics, Family and Youth (BMWFJ).

Tel.: +43 (1) 501 75 - 0 Fax: +43 (1) 501 75 - 900 Email: [email protected]

Austria Wirtschaftsservice Gesellschaft mbH, Ungargasse 37, 1030 Wien, Austria



WELCOM

ESPEAKERS

t back :: next u


Swiss Biotech Association www.swissbiotech.org

SwissBiotech – One Nation – One Biotech Cluster

Swiss Biotech unites the four leading biotech regions of Switzerland (BioAlps, BaselArea, Biopolo Ticino and Greater Zurich Area). The regions have early on combined efforts with the SWX Swiss Exchange which holds a leading position in terms of life-science listings and services.

The National Industry Association named Swiss Biotech Association Represents more than 150 companies to date and acts as the operational arm for the marketing alliance. Swiss Biotech raises Switzerland’s profile as an economic center in Europe and profiles the biotech industry with its key research institutions and companies.

Swiss Biotechs’ mission is to spread the message of Switzerland as one of the top biotech locations in the world. This will be achieved by presenting a comprehensive picture of the drivers of biotechnology including research, education, economics, finance and industry. The bases for success in biotechnology are the critical mass of research institutes and accelerated technology transfer. The early integration of industry and well-trained workforce is another critical success factor for rapid economic growth. More than 40 technology parks throughout the country support the increasingly important and successful TechTransfer process.

Further inquiries:SwissBiotech, Executive OfficeTel. +41 (0)44 455 56 78 [email protected]



WELCOM

ESPEAKERS


www.tiberendstrategicadvisors.com

Tiberend Strategic Advisors, Inc. is a corporate communications firm providing media strategy and execution for life science companies – biotech (therapeutics), medical devices and diagnostics. We work with both public and private emerging growth companies.

1. To enhance valuation

2. To build visibility for partnerships and strategic alliances

Tiberend Strategic Advisors, Inc.35 W. 35th Street, 5th Floor, New York, NY 10001-2205

Tel: 212.827.0020 Fax: 212.827.0028 Fax

Tiberend Strategic Advisors, Inc.

t back :: next u



WELCOM

ESPEAKERS


Torreya Partners LLC www.torreyapartners.com

Torreya Partners LLC is a leading boutique advisory firm that provides strategic advice and assistance with Mergers & Acquisitions, Partnering and Financings to life science companies worldwide. Torreya Partners provides the long-term thinking and objective advice required for life science companies to create lasting value. We take great pride in handling complex financial and strategic matters for some of the most sophisticated private and public life science companies in the world. Our reputation has been built on quality advice, excellence in deal execution and good outcomes for our clients. We bring the caliber of people and quality of relationships found in some of the largest investment banks along with the attentive, detailed service you expect from a boutique advisory firm. Torreya Partners has offices located in New York, Philadelphia and San Francisco.

UK12 St James’s SquareLondon SW1Y 4LB+44 0207 104 2310

New York117 East 55th Street New York, NY 10022 (212) 331-7843

t back :: next u



WELCOM

ESPEAKERS

Organisers

www.sachsforum.com

Sachs Associates is a London based international conference organiser which produces high profile events for the bio-pharmaceutical and financial community. These events are held In Europe and the USA; currently in Boston and Zurich.

The company was established in 1992 and ran emerging growth and emerging market investor forums in association with Dow Jones and then Bloomberg LP over a ten year period.

The benefits of conference participation with Sachs Associates may be summarised as follows:

Multimedia ExposureSachs Associates is uniquely able to provide its conference sponsors maximum exposure across extremely well focused electronic and print media. Regular extensive coverage of all the Company’s conferences is carried out through video streaming and extensive events coverage through major international financial news agencies,including Bloomberg, Dow Jones and Reuters. In addition, Sachs Associates has a number of long establishedrelationships with other financial press organisations globally, which allow further effective distribution onbehalf of its clients.

Eminent SpeakersSachs Associates is committed to ensuring that its events continue to provide forums with the participation ofthe most eminent speakers from the public and private sectors. Through its reputation and its long-establishedlocal relationships, the Company has attracted the very senior political and economic personalities as speakersat its events.

Sponsorship and Marketing Opportunities for forthcoming eventsSachs Associates has developed an extensive knowledge of the key individuals operating within the Europeanand global biotech industry. This together with a growing reputation for excellence puts Sachs Associates at theforefront of the industry and provides a powerful tool by which to increase the position of your company in thismarket.

Sponsorship of any of our events allows you to raise your company’s profile directly with your potential clients.All of our sponsorship packages are tailor made to each client, allowing your organisation to gain the most outof attending our industry driven events.

The following sponsorship and marketing opportunities are available at future conferences:• Conference Sponsor – including workshops and social events• Exhibition stands• Distribution of Promotional Material

If your company is interested in exhibiting or sponsorship opportunities please callMina Orda on +44 203 463 4890.

Sachs Associates www.sachsforum.comSachs Associates



WELCOM

ESPEAKERS

www.sachsforum.comEU

RO

PE

AN

L

IF

E

SC

IE

NC

E

CE

O

FO

RU

M

27 Belsize LaneLondon

NW3 5AS

Tel: +44 (0) 203 463 4890 Fax: +44 (0) 207 691 7919

We look forward to seeing you at:

2nd Annual Cancer Bio Partnering and Investment Forum

Promoting Public & Private Sector, Collaboration & Investment in Drug Development

19 March 2014 • New York Academy of Sciences • USA www.sachsforum.com/newyork14

14th Annual Biotech in Europe Forum

30 September – 01 October 2014 Congress Center Basel • Switzerland

2nd Annual Medtech & Diagnostics Innovations Summit

13 November 2014 • Düsseldorf • Germany

speakers 7th annual european life science ceo forum · partnering strategies through...

Documents